corporate responsibility report human race feel well live longercorporate responsibility report introduction introduction corporate responsibility gsk access medicine research ethical conduct employment practice supply chain environmental management work community datum summary gsk corporate responsibility report corporate responsibility report introduction welcome glaxosmithkline corporate responsibility report report explain approach wide range social ethical environmental issue associate business performance gsk report medicine researchbase pharmaceutical report cover corporate responsibility key pharmaceutical product company mission improve activity performance update target disease include quality human life enable people corporate responsibility report publish asthma chronic feel well live long business march obstructive pulmonary disease employ people country epilepsy depression datum relate calendar year consumer healthcare business include dental health disease central nervous state product overthecounter medicine system nutritional drink environmental datum cover calendar year hivaids herpe datum collect viral disease key statistic pharmaceutical consumer manufacturing infection site biological manufacture site bnexcept diabete operation pharmaceutical employee consumer research development site cancer turnover total major office location include available datum heart disease site operation cardiovascular disease pharmaceutical year require environmental datum urogenital disease consumer healthcare small office distribution centre note attach chart explain scope datum profit taxation collection process parameter detail vaccine number specify unit sale figure gsk make vaccine protect employee absolute number ie total consumption disease include energy water etc datum environment health hepatitis b safety section report externally diphtheria turnover location customer verify verification influenza scope datum relate worldwide polio operation indicate rotavirus bn use external guideline framework tetanus inform report relevant typhoid base report global reporting initiative bn guideline produce gri indexto whooping cough element guideline cover aid comparison company report bn consumer healthcare brand background information policy brand include approach cr available website overthecounter medicine wwwgskcomresponsibility beecham contac nicoretteniquitin panadol publish corporate responsibility review tum zovirax usa bn provide overview approach dental health aquafresh corporate responsibility available print europe bn macleans polident sensodyne website nutritional drink horlick international bn cr report report lucozade ribena rank th sustainability united nations environment programme standard poor global reporter survey international benchmark survey nonfinancial reporting gsk corporate responsibility report corporate responsibility report ceochairman letter believe healthcare company not sustainable concerned percent world population lucky resource pay new treatment believe access medicine essential vision gsk improve people health drive make talented scientist want work commitment poor country integral country represent viable commercial market new medicine need people medicine afford pure philanthropy right solution need great look new way tackle problem gsk involve public private partnership project research new medicine vaccine disease disproportionately affect develop country include hivaid malaria tb make key medicine vaccine accessible discount price negotiate licence thirdparty manufacturer produce generic version key hiv medicine report show effort start bear fruit preferential pricing voluntary licence help increase supply hivaids medicine subsaharan africa seven country complete fiveyear programme eliminate lymphatic filariasis albendazole treatment continue donate tablet disable incurable disease completely wipe vaccine exciting area percent vaccine dose produce sell preferential price immunisation campaign develop world save million life expect launch vaccine cervical cancer disease affect woman country great impact develop world screen programme catch early case room complacency effort need stakeholder resolve healthcare problem develop country proud contribution make know effort access medicine base solid foundation industry high profile subject criticism good medicine big difference quality length life rightly expect meet high standard integrity aspect work report give snapshot approach embed ethical culture gsk include apply high standard behaviour transparency rd promotion medicine treat people minimise impact business environment need play tackle major global issue climate change value input stakeholder welcome view report aspect corporate responsibility gsk sir christopher gent jp garni chairman chief executive officer gsk corporate responsibility report corporate responsibility report qa duncan learmouth appoint senior vice president corporate communication community partnership set vision cr gsk complete qa available cr report wwwgskcomresponsibility vision cr gsk gsk programme develop element want achieve high world philanthropy standard behaviour business part company want know s doubt business ve adopt theme performance need medicine away integrity successful need sure programme engage employee secondly need sustainable good way bring outside world decision make sure daytoday business understanding stakeholder great example longterm commitment view good decision provide notforprofit hiv medicine element desire real member world poor country local community operate immense stakeholder pressure subject include play wide global impossible turn blind eye community contribute well healthcare respond pressure outside employee want work think gsk company address challenge engage issue develop duty use scientific knowhow world experience unusual human capital difference public company believe lead essential sense integrity industry rd neglect disease preferential pricing voluntary licensing ahead not reduce price sector longterm product market approach programme involve high sustainable business degree partnership dialogue ngo adequate return will not able discover government organisation world new medicine immense pressure health organisation gate foundation competitor investor look issue pricing world gsk poor country sale marketing practice hot topic pharmaceutical industry need ensure research new medicine public regulatory need look expectation market product drug ensure gsk policy meet exceed change case drug need expectation change profitable s commercial practice run risk reduce demand new drug cancer alzheimer competitiveness proactive meeting huge unmet medical need encourage industry follow suit profitable problem disease tend present extreme scientific challenge big challenge require novel scientific approach carry difficult task find balance great risk failure disease develop need different stakeholder investor world present different problem great concerned primarily profit cr important need viable commercial market new affect longterm success product round problem work company quarter earning public private partnership press priority hand active rd neglect tropical disease think ngo society like debate metoo drug take concerned solve societys healthcare far new drug enable patient few problem dose day reduce effect like small improvement big difference treatment outcome gsk corporate responsibility report corporate responsibility report pharmaceutical industry role gsk play address criticise lack transparency climate change clinical trial result target reduce energy usage address concern believe ve adopt sustainable approach perception pharmaceutical link business position industry transparent think company address healthcare need partly not good job relatively small footprint communicating challenge face believe compare sector issue online clinical trial register go high priority address way address concern climate change important issue gsk communication datum clinical trial stakeholder need play tough area weigh balance risk tackle benefit medicine rarely straightforward datum not black white require interpretation judgement inevitably mean people different view knowledge change time new drug test actually talk medicine doctor straightforward communication important challenging pharmaceutical industry sustainable contract society return invest new drug generally year intellectual property protection product generic rd uncertain unpredictable period successful believe basic model good foster high level innovation course challenge industry continually look way improve rd productivity unique type product play personal role people live nowadays good health see right business people uncomfortable generally believe people accept need tradeoff like make profit health accept good way encourage discovery new medicine gsk corporate responsibility report corporate responsibility report corporate responsibility gsk cr important gsk strategy corporate responsibility gsk commit address key challenge achieve goal implement face pharmaceutical industry society business strategy aim operate way reflect value understand improve productivity research respond stakeholder view connect development business decision ethical social environmental concern support patient access new medicine corporate responsibility help achieve business goal focus business strategy structure report strategy support relationship key corporate responsibility integrate stakeholder include patient consumer business doctor government protect enhance reputation trust product improve ability attract retain motivate good people strengthen risk management process believe business make valuable contribution society develop marketing medicine improve people live know research development manufacture sale medicine raise ethical issue seek minimise negative impact business maximise positive benefit product operation build good product pipeline industry maximise potential current product benefit patientsconsumer society portfolio relevant responsibility issue include relevant responsibility issue include animal research ethical conduct conduct clinical trial standard supply chain patient safety environmental impact interaction patient group improve access medicine develop good place good people develop world well work relevant responsibility issue include relevant responsibility issue include rd disease develop world employment practice preferential pricing diversity voluntary licensing human right employee supply chain access medicine middle income develop health safety country resilience community investment gsk corporate responsibility report corporate responsibility report important corporate responsibility dtc advertising issue consistency commercial practice code corporate responsibility broad subject cover wide range issue need committee review sign prioritise issue order manage annual cr report effectively report clearly performance cr risk identify important material issue management significant business risk gsk engagement stakeholder coordinate risk oversight compliance risk management process knowledge council rocc rocc consider business pharmaceutical industry reputational corporate responsibility risk input lead identify cr issue background information rocc particularly relevant significant gsk risk management compliance gskcom research innovation contribute management structure healthcare develop medicine duncan learmouth senior vice president corporate vaccine meet need patient communication community partnership rupert bondy general counsel executive access medicine develop team member responsibility cr develop country believe daytoday management cr ethical conduct include sale marketing issue effectively business practice operation expert cr issue work environment include climate change coordination provide crossfunctional team impact pharmaceutical environment representative key business area representative senior manager direct access appropriate executive team member role oversee development manage cr implementation communication cr policy gsk ensure comprehensive corporate responsibility statement consistent approach take principle define approach key cr issues organisation provide guidance employee standard company commit small cr team coordinate view principlesin background section policy development report communication website socially responsible investment analyst cr governance details environment health safety corporate responsibility committee management ehs management crc nonexecutive board director provide assurance highlevel guidance approach cr environment health safety section ceo member corporate executive team report externally verify environmental actively involved cr participate crc assurance consultancy sgs purpose meeting assessment committee member sir christopher gent check ehs datum present accurate chair sir ian prosser dr daniel podolsky tom represent gsk performance de swaan find information fairly crc member terms reference background sectionof website critically review completeness relevance information present committee meet time year review policy progress cr principle assess effectiveness gsk data principle access medicine standard ethical management reporting system conduct research innovation global find sgss verification statement community partnership review annually response principle discuss year committee finding report section report externally board verify gsk extensive internal audit programme cover aspect committee review activity business number area include internal communication awareness access medicine employee inform corporate community investment responsibility copy cr overview brochure distribute reputation management employee directly spirit internal caring environment magazine spirit feature regular article cr relate topic standard ethical conduct gsk corporate responsibility report corporate responsibility report survey random selection difficult quantify extent employee awareness corporate engagement activity embed responsibility issue consider business operation include example important employee section report world different area business way engage respond survey stakeholder percent hear corporate investor benchmarking organisation responsibility hold meeting investor discuss cr issue percent recognise responsibility employee include onetoone meeting discuss key issue educational visit meeting ethical business conduct access medicine january host meeting investor health safety area vaccine facility belgium investor shown identify important presentation science vaccine visit area employee believe site research production area october company address investor visit manufacture plant dartford england investor show process make active ingredient product environmental management facility plant occasion investor stakeholder engagement opportunity meet question senior stakeholder engagement important gsk staff component approach manage december gsk dresdner bank run business responsibly help identify educational seminar patient safety important cr issue business understand investor senior physician charge stakeholder view expectation build global patient safety explain current drug trust key audience engage safety monitoring procedure gsk plan stakeholder tell work develop answer question learn expertise gsk interact wide investor range stakeholder include investor raise question issue patient year main issue raise related sale doctor marketing practice climate change access medicine clinical trial ethic particularly government regulator develop world approach issue public private health provider find report ngo multilateral organisation employee investor local community supplier scientific community peer company discussion take place normal course business example scientist meet regularly academic researcher pharmaceutical company gsk corporate responsibility report corporate responsibility report gsk receive follow rating agency organisation rating association british insurers gsk give rating disclosure board responsibility policy relate socialethical environmental issuesthis high possible rating dow jones sustainability index gsk include year indexindividual company score ranking long publish ftsegood index gsk include ftsegood index innov strategic value advisor rate rd company innovest global pharmaceutical sector reportgsk rate particularly highly area strategic governance claremont mckenna gsk receive b rating pharmaceutical sustainability reportingcarrie claremont mckennaa college evaluate company corporate responsibility issuesgsk thout company evaluate gsk report greenhouse gas emission thoughtout manage rate carbon disclosure project cdp read highly programme increase access response cdp website medicine develop world wwwcdprojectnet opinion leader suggestion cr benchmark study improve number area cosponsor benchmarking study include consultancy thinktank sustainability non gsk demonstrate commitment financial reporting pharmaceutical industry improve health globally sell gsk rate high overall compare pharmaceutical eg disease company sector prevention rank th embed cr company sustainabilityunep global company set target improve reporter study good practice sustainability performance report gsk pharmaceutical company gsk spend time listening stakeholder retain position premier league company score percent business develop strategy reduce communitys environment index impact climate change eh focus improve access establish stakeholder panel inform medicine middleincome country approach ehs management report external stakeholder represent customer opinion leader feel gsk cr report covered supplier regulator public interest group right issue report long overall investor senior gsk eh reduce readability gsk score point representative improve transparency reporting opinion leader year stakeholder expect opinion leader influential individual disclosure gsk work patient advocacy organisation expertise corporate group ethic management supply chain responsibility include ngo government approach human right issue representative investor journalist academics stakeholder consumer industry organisation follow table summarise interaction hold discussion group show information uk gather feedback opinion leader find cr performance report performance participant agree gsk approach corporate responsibility comprehensive gsk corporate responsibility report corporate responsibility report stakeholder engagement ngo engage international community ngo accesseducation public health programmesread investment public health initiative community investmenton engage regularly animal welfare organisation read animal researchon employee seek feedback employee regular employee survey employmenton summary result late survey consult employee change affect discuss business development work council european employee forumfor information internal communicationson government engage debate legislation seek influence policy decision affect gsk regulator engage government advance corporate responsibility objective government external affairson multilateral agency engage multilateral agency access public health initiative access medicineson doctor engage doctor way include medical representative run clinical trialssee researchand ethical conduct information manage issue engagement raise patient gsk researcher scientist meet patient focus patient initiativethis engagement influence understand disease research priority engage patient group directly patient advocacy leader summitsread patient advocacy conduct market research party understand patient need local community interaction local community manage individual gsk site work communitiesfor example initiative supplier hold global regional supplier review meeting senior gsk manager address interact supplier key issuesfor information supply chain scientific important gsk scientific academic debatesthis report contain community example interactionsfor discussion manage academic partnership relationship research gsk corporate responsibility report corporate responsibility report government external affair pharmaceutical industry highly regulate common european regulatory system regulation significant impact offer rapid approval new product business essential engage intellectual property incentive promote debate legislation seek influence policy research orphan medicine paediatric decision affect gsk fact major medicine medicine develop multinational corporation approach world government view stakeholder ngo implementation clinical trial regulation promote safety good clinical practice size global reach access government policy maker need use appropriate use health technology access responsibly benefit patient assessment hta believe htas business believe transparent independent transparent scientifically lobby public policy work robust mean ensure increase stakeholder trust confidence gsk right medicine reach right people ration tool policy govern interaction important stakeholder section cover increase individual involvement interaction government external responsibility personal healthcare include group include patient advocacy group improve access information information approach work medicine pharmaceutical company doctor healthcare professional available environment promote research research sectionof report development encourage inform debate background information approach benefit challenge new research public policy available external affair technology sectionof gskcom advocacy cr issue approach external affair engage government gsk external affair team monitor change stakeholder advance corporate responsibility propose reform legislation meet regularly objective example gsk government official explain view advocate improvement healthcare range public policy issue lobby issue develop world discussion affect pharmaceutical industry uk government multilateral conduct trade association agency ngo access medicine hire professional lobbyist support public policy work participate world aids conference hold toronto canada access medicine public policy work govern external affair code conduct back support mobilise malaria advocacy factual research analysis policy initiative generate political commitment background site sustain funding combat malaria community investment gsk believe legally culturally appropriate political donation legitimate way work regulator encourage support political process information acceptance alternative animal testing donation give report animal research annual report account political participate develop world health donation policygoverne contribution organization international clinical trial political candidate registry platform initiative standardise public policy activity way information medical study engage government wide available public range issue affect industry particular encouraged consistent approach advocate policy deliver patient safety report effect strong intellectual property right datum patient safety exclusivity protection encourage research lead effort develop industry code conduct development new medicine marketing ethic asian country vaccine marketing code practice pricing reimbursement system support innovative medicine provide great predictability transparency believe great liberalisation pharmaceutical pricing especially medicine pay government gsk corporate responsibility report corporate responsibility report position key issue publish position key issue gsk donation political party background sectionof website happy political organisation european union discuss position issue annual reportfor information legitimate party contact corporate contribution united states responsibility team csrcontactgskcom candidate finance primarily current position statement publish contribution company individual ngos wwwgskcomresponsibilityinclude party corporate contribution accept important way company clinical trial develop country engage political debate counterfeit medicine corporate contribution national political party develop world challenge access candidate run federal office medicine prohibit law importation medicine contribution state candidate gsk corporate fund give candidate intellectual property trip agreement state level state permit product diversion law donate approximately candidate stateheld office preparation flu pandemic split republicans approx percent membership trade association democrats approx percent gsk member trade organisation include contribution basis association british pharmaceutical political party gsk support candidate seek industry abpi environment appropriately reward high risk highinvestment industry believe free biotechnology industry organization bio market principle intellectual property right european federation pharmaceutical state publish information political industry efpia donation intellectual property owner association ipo political action committee contribution accordance federal election campaign japan pharmaceutical manufacturers act gsk political action committee pac association jpma facilitate voluntary political contribution swedish association pharmaceutical eligible employee pac control gsk industry lif participate employee legal right contribution candidate organization international investment ofii political party federal state level pharmaceutical research manufacturer pac contribution voluntary donation america phrma subject strict limitation example gsk pac contribute excess international federation pharmaceutical candidate federal office election manufacturer association ifpma pac contribution determine govern lobbying expenditure board pacparticipate gsk employee gsk spend federal lobbying activity company require law pac information report contribution report federal election congress accordance lobbying commission fec second half disclosure act include cost twoyear federal election cycle gsk employee salary benefit employee register pac contribute candidate state lobby government hire outside lobby federal office consultant support lobbying contact planning activity research background contribution canada running gsk washington dc government gsk donate cad approximately affair office support staff portion trade canada political candidate association fee associate federal lobbying province legal country collect separate datum contribution country lobby expenditure gsk donate aus approx australia political donation gsk make political donation corporate fund patient advocacy authorise law culturally patient advocacy group provide member appropriate support information live condition represent patient view contribute political advocate issue affect patient interest organisation canada australia important stakeholder gsk donation cover gsk policy engage aim patient political donation focus company gsk corporate responsibility report corporate responsibility report principle work world work wide range work patient group patient group patient group variety different disease area patient advocacy leader summit pal independence cancer asthma diabete hivaids way engage patient group patient association interest patient advocacy understanding hold summit japan political judgement patient need illness aim support european country include poland netherlands activity shall assure voice patient encourage romania latvia meeting patient constructive healthcare debate stakeholder group opportunity learn gsk tell cooperative matter company well support work transparency vital believe patient group play discuss debate key issue relate patient joint policy increasingly valuable role improve healthcare advocacy healthcare policy typically undertake protect independence credibility patient range workshop attendee include patient association group encourage obtain support glaxosmithkline shall session medium training share good practice financial nonfinancial diverse multiple base mutual respect source private public individual european patient group advisory board trust donation consult gsk policy work glaxosmithkline shall company patientcentric possible refrain undue approach board independent chair influence promote committed ensure work specific medicine patient group high level ethical representative series european group service disease area gsk direct standard transparency establish therapeutic interest work strong global principle patient association glaxosmithkline gsk commitment work ethically comply local patient group employee involve receive lawsgovernance formal training global principle work contribution society framework set standard operating procedure addition employee access believe business add social patient advocacy resource intranet site economic value society contribution product healthcare uk gsk advocacy work govern job wealth generate association british pharmaceutical industry abpi code practice state contribution healthcare write agreement company medicine vaccine enable people live patient group company publish long enjoy well quality life list patient group fund healthcare expensive especially patient list uk patient group receive funding need frequent visit doctor spend gsk go great time hospital example transparency extended list include spend healthcare go treat people patient group europethat receive funding chronic disease healthcare cost likely gsk give detail funding rise country population europe gsk develop standard operating age vaccine medicine reduce burden procedure sop working patient group healthcare system prevent disease enable initiative extend gsk people chronic disease work help region sop cover variety area patient control symptom few concern gsk work patient group state visit hospital gsk seek patient group gsk contribute healthcare way endorsement medicine disease prevention provide percent patient group overall funding effective intervention medicine treat percent fund vast majority disease instance actual percentage low innovation investment rd discover new additionally activity accompany medicine vaccine meet future write agreement healthcare need gsk work pharmaceutical company representative body encourage industrywide transparent ethical approach work patient group gsk corporate responsibility report corporate responsibility report disease prevention preventing disease well potential patient community investment support major avoid illness pain suffer well disease prevention programme develop society reduce healthcare cost country community investment support disease prevention effort way include vaccine global alliance plan completely vaccine protect crippling eliminate lf disfigure disease fatal disease include hepatitis b diphtheria world lead cause permanent seasonal flu polio tetanus whooping cough disability community investment currently supply vaccine disease global immunisation effort lead phase programme reduce diarrhoea eradication smallpox potential eradication relate disease encourage school child polio estimate save live develop country wash hand million people worldwide year community investment vaccination long term benefit intervention cost effective treat people key pharmaceutical product target sick reduce healthcare cost disease include prevent disease outbreak asthma chronic obstructive pulmonary reduce need expensive treatment disease hospitalisation epilepsy depression disease reduce permanent disability long central nervous system term effect disease hivaid herpe viral disease prevent loss productivity illness infection gsk vaccine diabetes distribute billion vaccine dose country develop cancer develop world average million dose heart disease cardiovascular disease day invest million vaccine research scientist work urogenital disease vaccine research centre major contribution healthcare vaccine available develop way country innovative tiere pricing prolong life gsk pioneer treatment model percent billion hivaid antiretroviral arvs vaccine produce go develop combivirhelp patient control effect world currently research new vaccine hiv infection year sell arvs disease include country subsaharan africa notfor particularly relevant develop country profit price access medicine access medicinespage prevent complication disease patient education support patient education diabete progressive patient not disease prevention initiative include receive right treatment suffer work patient advocacy group severe effect day diabetes produce patient information leaflet medicine cause estimate amputation pack doctor surgery publish case blindness people information disease preventionon website experience kidney failure avandia antismoking estimate diabetes treatment help patient control million people die prematurely year result symptom delay progression smoking make smoking cessation disease prevent complication avandia effective way improve health gsk seven million nicotine replacement therapy brand people worldwide nicoderm nicorette help improve quality life million smoker quit make medicine asthma significant contribution public health diabete help patient chronic disease live productive life gsk preventative treatment asthma seretideadvair control symptom asthma prevent asthma attack cure infection produce antibiotic treat respiratory tract infection donate antibiotic help relief effort disaster area communityon gsk corporate responsibility report corporate responsibility report value uk economy innovation british pharma despite revolutionary advance healthcare health organization predict copd group comprise disease cure lead cause death ukbased company gsk treatment improve gsk study involve patient astrazeneca commission continued research innovation essential year identify relevant marker report office health economic ohe indepen help predict disease progression believe rd new medicine dent research organisation important element corporate responsibility disease cause genetic factor company value uk economy company gsk invest billion make difficult cure prevent employ people rd research bodys immune system report concept enable develop safe effective economic rent net pipeline additional income wealth prescription medicine vaccine target vaccine protect great bring uk number disease clinical development current project include company excess income research asthma cancer depression diabete economic value generate labour capital epilepsy heart disease hivaid influenza irritable contribute country operate good alternative use bowel syndrome osteoporosis schizophrenia create wealth employment pay stroke tb taxis purchase product service ohe state estimate net economic rent direct financial contribution product expect launch major new vaccine earn enterprise contribute indirectly economic growth year economy expect prevent treat disease close zero ie yield human papilloma virus vaccine prevent economic value detail financial information available cervical cancer significantly annual report key figure good alternative use usa launch vaccine rotavirus global business capital labour employ induce gastroenteritis strengthen global figure gsk astrazenecas rotavirus vaccine uptake europe economic rent manufact international market sale ure rd activity uk estimate vaccine pneumococcal disease rd investment billion annually nontypeable haemophilus influenzae possibly high infection cause otitis medium payment gsk contribute approximately employee percent figure number vaccine seasonal read copy avian flu base gsk unique expertise supplier na na report background section adjuvant technology include new government taxation website generation adjuvante seasonal flu vaccine study rank elderly people community investment gsk value uk economy vaccine combination meningitis na available highly uk government department expert predict major flu trade industry dti pandemic decade cause hn value add scoreboard list strain bird flu gsk actively prepare company make large potential crisis pivotal clinical trial gsk new human right contribution value add generation hn influenza vaccine carry uk europe gsk belgium show low dose human right broad subject relevant rank thin uk thin europe high pharma antigen g combine gsk novel gsk number different contexts ceutical company value adjuvant system elicit strong seroprotective committed uphold human right add calculate response gsk vaccine believe sphere influence great control billion potential offer protection drift employee human right operation variant hn virus influence human right supplier investment rd stimulate proactive prepandemic vaccination campaign wide society economic growth gsk rank addition increase production relenza thin uk dtis rd treatment influenza review gsk sphere influence scoreboard rank pipeline annual report reason human right global company value rd investment extensive rd programme disease seriously high rank uk company disproportionately affect develop country achieve high standard human right wwwdtigovukinnovation believe gsk company research support reputation goal new vaccine treatment hivaid tb operational excellence malaria world health organization help good employee priority disease work supplier match research cause disease standard help ensure smooth research potential new medicine operation supplier contract invest research increase understand reliable supply high quality product human body cause disease support good relationship example launch eclipse non community near site drug study improve understand chronic obstructive pulmonary disease copd world gsk corporate responsibility report corporate responsibility report approach human right guide un wide variety biological material universal declaration human right oecd biomedical research include human guideline multinational enterprise core material nonhuman material find human labour standard set international labour bacteria viruse animal plant organisation obtain source indigenous unique country employee community commonly cultivate direct employee educate bred staple commercial product obtain skilled people risk human right issue ordinary commercial channel occur relatively low believe employment standard issue diversity today gsk pharmaceutical research equal opportunity health safety provide base screen large number synthetic adequate safeguard human right chemical compound natural resource employee information employment currently access benefit practiceson sharing agreement place gsk undertake development work indigenous supplier genetic resource associate traditional expect supplier contractor business knowledge arise gsk natural product partner meet standard human collection programme access resource right gsk recognise supplier obtain accordance local law seek influence supplier contract negotiate require adopt high standard human right add appropriate authority ensure human right clause contract clear benefit return country auditing supplier information supply origin example royalty share chainon net profit policy biodiversity community society human right relevant relationship improve healthcare particularly develop wide community stakeholder world great challenge world example face gsk commit play country poor human right record improve access medicine contribute stakeholder concern healthcare develop world presence country poor human research new treatment vaccine right record sudan north korea make medicine available affordable burma respect concern preferential price negotiate voluntary licence medicine vaccine need local generic manufacturer population product need register community investment information government sell access medicineson community require interaction aspect investmenton government believe un engage government multilateral agency people deny access medicine ngo help improve access medicine regime operate country develop seven point plan use un document advocacy effort information local community seek reduce environmental impact site operate safely foster good relationship local community indigenous material traditional knowledge world lead pharmaceutical company gsk fully support convention biological diversitys role provide framework conservation biological diversity sustainable use component respect traditional knowledge support cbd objective provide fair equitable share benefit arise use genetic resource gsk corporate responsibility report corporate responsibility report access medicine million poor people develop develop country struggle medicine need support effort improve access healthcare worker aids pandemic make medicine section explain situation bad depriving community great asset healthy productive people contribution develop world tackle crisis complex challenge require research preferential pricing partnership visionary leadership poverty huge barrier voluntary licence community investment progress significant political extra resource important public health initiative need aid development build healthcare infrastructure disease programme need pricing arrangement discount card coordinate ensure health system middleincome country benefit patient assistance program discount card believe responsibility help uninsured patient government intergovernmental agency believe response right supplement work ngo deliver thing make good business sense healthcare country company adapt business practice pharmaceutical industry play significant role address challenge leader support effort future competitive market talente important contribution people help attract retain good people research development disease disproportionately affect develop differential pricing increase affordability patient country believe gsk currently whilst maintain support intellectual company research new vaccine property system intellectual property right treatment hivaid tb malaria essential pharmaceutical industry world health organization priority able invest disease research conduct rd new medicine vaccine public private partnership find innovative way help poor people preferential pricing specially reduce price develop develop country access antiretroviral arvs antimalarial medicine address ethical reputational vaccine ship commercial imperative reason million combivirand epivirtablet access medicine strategic business driver forprofit price treatment hivaid gsk poor country world support underserved community seek innovative partnership gsk worldwide donation funding grant voluntary licence practical support community investment manufacture supply generic version develop world lead arvs treat hivaids africa poverty cause healthcare crisis part active partnership roll develop world million people malaria stop tb access reliable food clean water community investment public health mind adequate healthcare despite unprecedented initiative partnership foster effective resource available public health healthcare include major programme government unable fund clinic tackle lymphatic filariasis malaria hivaids staff need deliver basic healthcare diarrhoeal disease community investment world bank estimate person research development year need provide basic health research development rd new drug service average spend subsaharan vaccine essential element improve africa african region health develop world suffer percent global burden effective treatment widespread life disease percent world threaten disease exist treatment health worker migration african health worker disease malaria effective wealthy market exacerbate situation drug resistance globally shortage million gsk corporate responsibility report corporate responsibility report hivaids affect develop disease develop world ddw access healthcare develop country commercial market include ddw drug discovery centre tre responsibility new treatment encourage investment canto rd site spain scientist access healthcare develop world remain require rd gsk industry leader base clinical development expert complex issue believe research hivaid treatment prevention uk ddw project prioritise accord holistic approach social public health benefit embrace prevention disease disproportionately commercial return similar group exist treatment work affect develop world lack resource vaccine organisation base belgium stakeholder role play healthcare mean viable pharmaceutical company commercial market new treatment public total gsk conduct rd disease medicine affordable private partnership ppps help address particular relevance develop world develop country problem include clinical programme medicine invest research disease vaccine disease seven develop world new gsk collaborate ppp include project disease disproportionately treatment urgently need medicine malaria venture mmv global alliance tb drug development tb alliance affect develop country wealthy nation summarise welcome new funding come aeras global tb vaccine foundation aeras global fund malaria vaccine initiative mvi international fight aids tb malaria aids vaccine initiative iavi gate foundation pepfar hivaid malaria leishmaniasis dengue fever hepatitis c president emergency plan gsk create dedicated group hepatitis e n meningitis cervical cancer tb chlamydia aids relief pharmaceutical rd organisation focus pneumococcal disease fund inadequate resource need fund research purchase medicine development pipeline end disease relevant develop world discourage export train healthcare worker focus preclinical activity phase phase ii phase iii marketed develop country develop country hiv integrase inhibitor retrovir epivir genuine political commitment hiv entry inhibitor combivirziagen address stigma remove nnrti trizivir agenerase import tariff prioritise kivexatelzir healthcare national budgets middleincome country vaccine hiv malaria synflorix rotarix accept responsibility malaria hiv dna p falciparum pneumococcus rotavirus seek low price p vivax antiviral tb disease havrix offer world poor hiv vaccine hepatitis e cervarix hepatitis country chlamydia dengue fever cervical cancer engerixb develop seven nmeningitis hepatitis b point planfor sustainable combination twinrix approach improve hep ab healthcare develop infanrixtritanrix world use dpt family advocacy effort diptheriatetanus include pertussis boostrix submission uk department international dtp acellular development dfid polio sabin consultation white polio paper eliminate world priorix poverty make governance measlesmump work poor rubella health strategy typherix typhoid hiberix submission g haemophilus influenzae government ahead st petersburg summit type b mencevaxacw facetoface meeting meningitis hilary benn uk international development secretary un malaria tefenoquine cda lapdaphalfan secretary general kofiannan malarone uk government official white house official eu tb official ngo representatives sitamaquine zentel hepatitis c visceral deworme agent interaction unaid leishmaniasis pentostam unitaid new visceral leishmaniasis international drug purchase banocide facility world health lymphatic filariasis organization gsk india detailed information product pipeline find annual report gsk corporate responsibility report corporate responsibility report s different rd progress hivaid medicine develop vaccine world malaria gsk leader global effort develop gsk scientist work vaccine aids vaccine involve aids treatment project disease gsk work malaria vaccine vaccine research decade disproportionately affect develop country year clinical trial malaria vaccine today pursue separate vaccine access medicine priority child show vaccine remain technology successful aid vaccine need right start rd efficacious month reduce severe combine approach process malaria percent child year research new clinical investigation need result gsk institut pasteur work treatment produce target indicate potential help save million develop aids vaccine fuse gene product profile tpp outline children live additional phase ii clinical hiv virus exist measle vaccine characteristic trial vaccine initiate mozambique project support euro million look new molecule kenya tanzania gabon ghana million grant european union safety efficacy tpp new ddw treatment support grant malaria vaccine public private partnership emphasise factor initiative pathfunde bill melinda international aids vaccine initiative iavi gates foundation evaluate develop aids vaccine nonhuman primate heat humidity resistance product vaccine different setting young adenovirus vector technology collaboration able survive child trial successful partner aids vaccine research iavi hot climate initiate largescale phase iii clinical trial major vaccine company facilitate refrigeration result continue positive vaccine research vaccine type hiv facility submit regulatory approval early circulate predominantly africa ease use easy use setting treatment gsk biological inhouse aids vaccine limited healthcare work closely medicine development project company prop facility example malaria venture subsidise scientist rietary adjuvant system technology phase aday tablet tre canto facility world health clinical trial conduct vaccine take home organization academic partner united states partnership preferable injectable develop cda affordable fixeddose artemisinin national institutes health hiv vaccine trial medicine administer hospital combination treatment drugresistant malaria network belgium ghent clinic africa phase iii clinical trial initiate university trial complete site africa additional phase iii respectively demonstrate vaccine safe affordability price important study plan involve infant produce strong immune response factor look age month year aim phase trial hivinfecte volunteer molecule formulation submit cda regulatory approval early initiate late collaboration straightforward march identify lead candidate partner aid research center massachusetts manufacture inexpensive produce gw forward development general hospital boston result pyridone project backup currently analyse followup approach candidate gw drug explore similar strategy new antigen potential highly active drugresistant name f phase clinical trial f vaccine strain malaria toxicity candidate schedule begin near future issue affect previous candidate class belgium significant chemical pharmaceutical develop fourth approach aim develop improve ment undertake antimalarial drug adjuvanted envelope env protein vaccine able gsk ntert butyl isoquine plan produce neutralise antibody provide start clinical study human partner last protection infection hiv funding available drug relatively approach currently preclinical evaluation straightforward synthesise manufacture treatment potential relatively december discontinue clinical inexpensive development brecanavir protease inhibitor clinical datum tafenoquine new antimalarial patient multidrug resistant hiv infection develop partnership military unable develop oral dosage show tafenoquinecontaine formulation consistently deliver combination regiman work fast exist correct dosage brecanavir patient therapy treatment p vivaxmalaria scientist work new hiv medicine help address concern emerge different drug class integrase inhibitor resistance exist treatment discovery programme active lead discussion fund additional candidate c develop development work treatment p vivax partnership shionogi currently phase ii malaria plan proceed clinical development new hiv entry inhibitor non development nucleoside reverse transcriptase inhibitor nnrti candidate enter pipeline gsk corporate responsibility report corporate responsibility report expert unicef state access partnership stellenbosch university south appropriate arv tablet oppose arv africa gsk support grant application fund liquid formulation facilitate treatment programme identify biomarker people child old able swallow tablet respond specific treatment develop score tablet key arvs biomarker predict epivir ziagen combivir broken patient respond quickly treatment tb small dose suitable treatment likely recur child simplify treatment help rotavirus physician carer administer right dose rotavirus infection lead cause severe efficiently safely child expect diarrhoea vomiting gastroenteritis child submit score tablet registration kill child want continue play important role year child minute develop treatment hiv child support country vaccine rotarix prevention paediatric clinical study involve rotavirus induce gastroenteritis launch child resourcepoor country mexico january approve country register provide arvs international hiv registration collaborative research trial programme support develop world vaccine clinical study run party currently national immunisation programme new support clinical study involve bear baby develop country include patient study take place sub brazil el salvador mexico panama venezuela saharan africa include study distribute million dose launch prevention mothertochild transmission early gsk receive prequalification status prophylactic property study child rotavirus vaccine world health mention hivtb coinfection organization require un adult treatment strategy study organisation gaviformerly know intended advance knowledge use global alliance vaccine immunisation arvs resourcepoor setting help purchase vaccine timely increase access arvs complement decision gavi late tuberculosis tb provide funding support introduction tb kill million people year lead rotavirus vaccine develop country cause death people aid cervical cancer develop world new drug tb cervical cancer common cause cancer discover year death woman develop world current vaccine publish datum suggest cervarix vaccine gsk aeras global tb vaccine reduce percent woman lifetime risk foundationare develop gsk tb candidate develop cervical cancer apply vaccine earlystage clinical trial registration vaccine europe belgium show vaccine safe country international region tolerate produce strong immune response track file regulatory approval begin additional trial involve adult april commit previously infect tb vaccinate make cervarixwidely available bacillus calmettegurin bcg plan conduct available lowincome country preferential study africa location test price gsk tiere pricing model safety efficacy vaccine candidate vaccine population highly affected tb conduct clinical study use treatment vaccine low income setting launch joint drug discovery leishmaniasis partnership global alliance tb drug sitamaquine potential new onceaday oral developmenttb alliance tb alliance aim treatment visceral leishmaniasis disease accelerate development affordable drug affect half million people year develop shorten treatment effective world usually fatal untreated gsk multidrugresistant strain tb compound provide funding project new screened ensure take treatment visceral leishmaniasis urgently hiv treatment tb alliance support need current medicine fulltime scientist work exclusively tb impractical ineffective drug drug programme tre canto gsk contribute resistance simply unaffordable sitamaquine matching number staff remain show good efficacy phase ii trial trial overhead cost million compound suggest short treatment period test antitb activity achieve half week preclinical tb project underway need current treatment low cost suggest sitamaquine truly accessible treatment visceral leishmaniasis affect poor poor gsk corporate responsibility report corporate responsibility report public private partnership ppps preferential pricing ppp ppp company gsk poverty lack political insufficient medical supply licencee supply provide rd technology infrastructure hospital clinic health worker million tablet version epivirand manufacture distribution big barrier access healthcare combivirto africa expertise academic institution develop country provide research continue look new customer disease area knowledge public affordability medicine important nfp arvs country regularly review sector partner government element nfp price organisation licencee able produce firstline arvs low gate foundation help fund ability government patient pay development delivery cost cost increase share business medicine government inter ensure medicine governmental agency significant massive scaleup treatment hivaid people need fund usually channel additional financial resource available solve planned global community organisation problem year negotiate agreement contract medicine malaria manufacturer ensure capacity price medicine sell area venture contribute meeting demand gsk help address ppp need publish new treatment guideline gsk want invest research make arvs antimalarial available tackle disease blight develop country affordable price patient hiv arv abacavir develop world recommend firstline treatment option major commitment preferential dilemma reduce nfp price abacavir pricing include notforprofit nfp price profitable sustain business contain arvs percent continue develop new world poor country discount price new arvs kivexaand telzir available nfp medicine business model wealthy develop middleincome country price work case prospect concern pharmaceutical commercial return factor supply chain taxis company register unfortunately lack resource tariff distributor markup significantly essential medicine develop country mean limited market increase price medicine factor new treatment disease prevent country take advantage control address disproportionately affect preferential pricing offer continue review government develop country ppp registration need key arvs model business middleincome develop country target develop country ensure epivir public sector work continue negotiate public sector price case retrovirand combivirare available widely offer solution bycase basis improve affordability necessary possible partnership work practice gsk vaccine available preferential price current focus abacavir drug discovery take place use tiere pricing structure vaccine price abacavircontaine arvs available dedicated disease develop world little tenth location prioritise effort develop world discovery develop country work great medical need particular centre tre canto gsk multinational organisation unicef pepfar country develop country provide facility meet run cost world health organization pan american significant hiv burden highquality gsk scientist tre health organisation government non alternative abacavir available canto half governmental organisation provide appropriate product diversion notforprofit medicine subsidise partner affordable vaccine develop country organisation medicine illegally ship sale wealthy include basic polio vaccine specially malaria venture mmv country deny treatment patient poorer develop combination vaccine target global alliance tb drug country antidiversion measure include development tb alliance disease billion vaccine access pack red white tablet ship percent go develop compound clinical combivir epivirtablet epivirsolution trizivir world low previous year development gsk provide retrovirsolution register clinical regulatory timing significant tender country gsk company manufacturing expertise progress receive positive opinion epivir combivir resources global ship million tablet nfp combivirand red colour tablet european medicine rd supply network partner help fund cost million tablet nfp epivirto develop evaluation agency emea article run clinical trial address world compare million million regulatory procedure medicine intend issue access distribution tablet respectively use outside eu serve speed reduce cost registration red coloured tablet develop development get new decrease expect primarily country product patient fast customer purchase arvs generic research programme manufacturer include licensed gsk oversee joint steering positive indication license policy committee representative work gsk partner affect price year generic manufacturer license new treatment gsk significantly increase importantly term manufacturing capacity ability supply large agreement quantity arvs low price welcome commit new trend give customer subsaharan africa treatment result ppps accessible develop great choice contribute well security world affordable price gsk corporate responsibility report corporate responsibility report report unled accelerate access initiative aai suggest september people live hivaids develop country receive treatment arv supply seven pharmaceutical company aai compare people treatment include patient africa extend preferential pricing consider extend preferential price africa wide range product number commercial factor overall market environment consider finding country pilot study inform evaluation voluntary licensing partnership gsk want play global response hivaid pandemic preferential pricing arrangement enable supply highly discount safe quality product long need situation voluntary licence help increase supply medicine voluntary licence vl enable local manufacturer produce sell generic version product grant vl negotiate licencing agreement arvs africa include new licence agree south africa company vls cover individual country trade block whilst cover subsaharan africa vl universal solution hivaid specific response particular set circumstance decision grant vl depend number factor include severity hivaid epidemic country local healthcare provision economic manufacturing environment select appropriate licensee key need sure manufacturer able provide longterm supply good quality medicine implement safeguard prevent diversion medicine wealthy market gsk corporate responsibility report noillim stelbat fo rebmun notforprofit price supply preferentially price discussion use summary combivirand epivirtablet compulsory licence intellectual property right take away right holder medicine compulsory license flexibility hivaid arvs world trade organisation trip agreement malaria treatment gsk licencee intellectual property gsk believe widespread customer use compulsory licence undermine public sector customer intellectual property framework counter forprofit organisation productive long term rd new eligible country private employer subsaharan africa treatment especially commercial market provide treatment non exist hivaid depend protection insure staff intellectual property country develop country subsaharan africa country eligible global fund pepfar middleincome country project country total eligibility notfor middleincome country economically profit price background develop healthcare demand section website outstrip available resource challenge detail bad grow aid epidemic cost middleincome country combivir lead arv available day nfp afford supply product low price price include delivery world poor country insurance cost adequate return wealthy market recognise middle nfp price applicable income country need assistance order size dependent large order negotiate preferential pricing arrangement quantitie middleincome country casebycase basis bilaterally dialogue long nfp price sustainable government believe good approach profit disease burden resource available cover address vary significantly country country manufacturing distribution country arrangement cost continue combine viable sustainable commercial return supply longterm gsk improve affordability healthcare system concern develop country introduce discount card senior citizen develop world activity russia announce agreement supply arvs russian government discount price direct federal purchase antiretroviral medicine russia gsk supply treatment pack russian government hiv medicine combivir epivirand ziagen dispense hospital centre country agreement contribute russian government target reach patient end target double china september sign voluntary licence simcere chinese manufacturer grant right manufacture sell zanamivir relenza contain product china indonesia thailand vietnam ldc relenzais anti viral help treat influenza half human case flu cause hn virus occur asiapacific regioncorporate responsibility report intellectual property right india india develop large generic industry partly significant reduction year result national legislation permit reflect introduction new drug benefit patent protection pharmaceutical product medicare programme know comply wto trade relate medicare prior medicare patient aspect intellectual property right trip prescription coverage medicine agreement india introduce legislation allow patient enrol medicare patent pharmaceutical product plan ineligible exist patient context access medicine debate assistance programme bridge access argue obligation india result commitment access recognise end provision cheap generic drug coverage patient undermine future availability affordable need assistance new programme gsk innovative product accessprovide extra help low income senior disabled medicare patient need gsk believe intellectual property get medicine programme allow protection provision set trip vital spend pocket development medicine meet unmet medical prescription medicine income need world robust ip system percent percent essential encourage researchbase company percent oncology product federal undertake risky hugely expensive rd poverty level apply eligible obtain gsk discover new well medicine vaccine medicine free remainder generic medicine wwwgskaccesscomfor information market india affect expect new programme increase number introduction patent protection continue patient assistance programme available india way today believe public health safeguard trip agreement january gsk pharma prevent access problem future ceutical company create discount saving programme improve access medicine root cause develop country inability uninsured americans eligible address healthcare problem lie medicare rx accesscard provide patent system lack funding saving percent lack political inadequate healthcare medicine approximately million people infrastructure factor affect percent people intellectual property right implementation prescription insurance eligible enroll trip india participate company enrol people receive million day prescription save million base wac gsk provide discount million develop world patient day prescription access medicine issue orange cardsin middle income country develop world develop country orange cardin ukraine give asthma patient afford medicine chronic obstructive pulmonary disease patient need particular problem average discount people health insurance gsk percent popular presentation develop patient assistance program gsk seretide asthma medicine asthma patient discount saving card help patient age suffer disability affect insurance chernobyl nuclear disaster eligible introduce discount saving card eligibility assess patient doctor middleincome country enable patient receive medicine participate qualifying patient obtain prescription medicine pharmacy hotline number set discount price help patient find near pharmacy orange card discount total programme patient assistance program provide prescription medicine lowincome uninsured patient free lithuania orange card give senior citizen minimal cost gsk operate disabled average discount percent programme include commitment access patient copayment gsk prescription cover cancer treatment bridge medicine far patient access cover medicine apply orange card patient patient register phone pharmacy percent pharmacy patient advocate receive medicine lithuania register participate local pharmacy mail order patient receive discount worth patient receive gsk medicine worth million programme compare million value medicine calculate wholesale acquisition cost wac gsk corporate responsibility report corporate responsibility report gsk orange cardin bulgaria provide lowincome patient discount gsk medicine treat chronic disease asthma chronic obstructive pulmonary disease diabetes broaden scope orange cardin response change bulgarian reimbursement system mean patient chronic disease long access state assistance currently prescribe medicine orange cardprovide direct benefit form subsidy patient suffer important chronic disease bulgaria asthma diabete benign prostate hyperplasia gsk investment orange cardin bulgaria euro million million summary gsk discount programme country gsk programme number patient value benefit patient patient assistance program free minimal cost medicine lowincome receive million uninsured patient prescription million rx access discount lowincome uninsured patient receive million joint industry programme prescription million bulgaria orange card discount lowincome euro million patient chronic disease approx million lithuania orange card discount senior citizen disabled people ukraine orange card discount asthma copd medicine patient available gsk corporate responsibility report corporate responsibility report research research development rd new medicine vaccine core business make significant contribution society product pipeline new medicine vaccine bring animal research gsk rd pipeline include huge benefit health quality life potential new treatment animal research test essential million people year vaccine component understand disease debilitate condition continue rd remain important evaluate safety effectiveness new vaccine include debilitate life prescription overthecounter medicine threaten illness effective alzheimer disease treatment treatment safety regulation require test new asthma significantly improve medicine animal test atherosclerosis clinical trial human vaccine goal build good product pipeline cancer industry invest billion test animal time new batch produce depression billion employ people diabete rd gsk animal research laboratory europe asia animal research conduct heart disease research aim address unmet medical need external contractor behalf pipeline include compound potential hivaid represent additional percent animal major contribution healthcare influenza estimate animal research account develop country access medicine percent gsk research expenditure malaria rd process seek view rheumatoid arthritis patient inform research focus patient percent animal gsk need drive innovation bring commercial rodent rat mice guinea pig rabbit tb success remain percent include fish ferret pig dog cat primate recognise biomedical pharmaceutical research raise ethical concern use animal gsk new technology objective report clinical trial result commit attain mouse high ethical scientific standard rd work section explain approach rat animal research effort reduce guinea pig refine replace animal testing rodent conduct clinical trial ensure rabbit gsk sponsor clinical trial carry high ethical standard irrespective conduct ultimately gsk like important training auditing clinical trial benefit research achieve use train gsk employee involve clinical trial experimentation potential cause check trial carry pain distress animal believe good clinical practice gcp standard achieve foreseeable future gsk commit rs reduction clinical trial information result refinement replacement animal research publicly disclose trial information result achieve high standard animal welfare journal article gsk clinical trial goal use animal scientifically register public database necessary use scientifically feasible patient safety monitor safety minimise pain distress medicine approach continue impact background information approach new small increase absolute number technology include pharmacogenetic animal baseline researchand use transgenic animal growth rd activity continue greatly available website exceed increase animal use start estimate external animal use record external animal use represent total animal use laboratoriesthis change represent rise improvement reporting datum diverse external collaboration use baseline comparison year able collect reliable datathe increase use mouse usedespecially vaccine test gsk corporate responsibility report corporate responsibility report change rd activity compare change number animal gsk research laboratory rd activity animal datum include animal research conduct external contractor behalfrd activity combine rd budget vaccine salesthe main driver animal usevaccine sale include vaccine test animal time new batch produce gsk corporate responsibility report ecni egnahc change rd activity compare change number animal gsk research laboratory year animal rd activity corporate responsibility report recent gsk advance rs regulation internal control replace wildcaught animal research laboratory comply animal welfare award recognise employee primate safety national law animal welfare regulator carry outstanding advance test oral polio vaccine regular unannounced inspection site implement rs research team primate breed look smoking cessation product receive captivity propose research testing animal reduce number award reduce percent number consider gsk ethical review committee gsk primate rat study addictive property laboratorie external laboratory purpose percent smoking product compare conduct research behalf follow progress replacement code practice animal research share good practice primate include good practice standard animal care fund uk national centre rs safety testing oral polio use ncrs prize recognise good new vaccine genetically technique implement rs modify mice date independent accreditation association prize money technique achieve remain subject accreditation assessment laboratory regulatory approval animal care aaalac international way reduce number mouse subject invasive procedure bacterial disease replace rat laboratory demonstrate meet good research supply brain tissue practice standard animal laboratory rat stem cell culture accredit aaalac locate industry partner association continuously produce belgium italy spain uk british pharmaceutical industry funding cell need accreditation cover percent threeyear job post ncrs encourage use animal avoid use rat year animal gskowne laboratory share good practice aim achieve aaalac accreditation increase donate internal guide refining number macaque laboratory collection blood sample laboratory monkey house pair expand business new market animal available free ncrs allow social increase vaccine production work website interaction improve animal wellbee external partner develop new medicine involve initiative conduct animal research testing introduce use encourage research rs stimulate country worldwide assess impact catheter automate sharing good practice animal research blood collection system change programme animal gsk significantly reduce research update policy number rat review study sponsor externally take work group run ncrs pharmacokinetic study replace reduce use primate study absorption r research distribution metabolism implement rs commit excretion medicine support university federation new approach replace animal study alternative animal welfare project improve housing significantly reduce animal method possible husbandry laboratory animal use percent reducingthe number animal commonly type participate european rspca frame study study industry initiative reduce use dog information refiningstudie minimise pain maximise safety testing implement rs available information obtain animal website support national academys institute example currently replace use laboratory animal research johns primate mice vaccine batch testing hopkin center alternative animal look way use advance test quality control process vaccine production advocacy change testing requirement eventually work stakeholder encourage reduction necessary test batch vaccine refinement replacement animal research animal test training awareness join european partnership alternative provide training rs staff animal testing collaboration involve care use animal publish european commission major quarterly news bulletin rs raise company seven industry sector awarness work range stakeholder ensure ethical review committee gsk scientist impact animal reach chemical statistician senior manager animal technician initiative address believe veterinarian encourage rs culture gsk exist datum record longterm human seminar recommend practice exposure record modern technique guideline scientific procedure animal use animal provide welfare datum require product testing establish product use time close laboratory japanacquire laboratory croatia canada establish gskmanage laboratory singapore usgive current total gsk laboratory use animal gsk corporate responsibility report corporate responsibility report give evidence uk academy medical conduct clinical policy payment science study use nonhuman healthcare practitioner trial primate research confirm institution conduct gsk sponsor gsksupporte strong justification essential use safety effectiveness new medicine clinical study conclude vaccine evaluate human clinical trial clinical trial investigator mean address clearly define approve marketing select solely question particular biological medical regulator approval trial qualification conduct importance strong scientific demonstrate product safe effective clinical research history moral case carefully regulate use benefit outweigh risk potential gsk product take account nonhuman primate effect payment practitioner participate study animal pain new product typically test reflect fair market value distress research study conduct stage clinical trial involve healthy work perform laboratory animal science association individual patient relevant disease payment offer animal procedure committee assess influence project clinical severity pain distress judgement development retrospectively report study find enrol maintain research institution standard clinical trial participant clinical study record pain distress experience gsk clinical trial carry individual animal conclude make conduct accord good clinical information public useful practice gcp guideline develop increase transparency study look international conference harmonisation ich way introduce principle contain world medical excessive bureaucracy association declaration helsinki ethical principle medical research involve communicate approach human subject people hold strong view animal research testing believe important explain ich guideline provide internationally need animal research testing open accept ethical scientific quality standard designing conducting recording reporting trial cover issue selection laboratory host visit school college train trial investigator gain informed animal welfare organisation consent trial participant monitor visit uk schools host quality assurance site visit host regular science literacy teacher workshop animal research trial protocol plan clinical trial pennsylvania north carolina association conduct review external regulatory biomedical research teacher agency relevant country require take protocol consider relevant ethical review committee cover site engage regularly animal welfare study place organisation investor contribute debate medium article ethic review committee compose lay animal research uk time thapril people medical professional scientist follow visit gsk uk animal laboratory assess trial justify design conduct accord sustainability corporate responsibility appropriate ethical standard ethic committee consultancy thinktank benchmarke power reject stop clinical trial report animal research conclude overall comprehensive discussion safety datum routinely collect animal research industry report development programme report animal welfare concern integrate regulator line applicable regulation data gsk operation contracting review gsk ongoing basis safety signal event necessarily cause protest treatment require exploration gsk accept right lawful protest animal global safety board gsb lead chief research free society condemn medical officer compose senior physician use violence intimidation scientist gsb oversee safety oppose animal use public stance investigational market compound extremism compliment approve administration investigational medium uk guardian thmay uk compound human define dose prime minister uk sunday telegraph th duration treatment consider safe robustness openness welcome gsk global safety board responsible apparent shift uk away extremism approval pivotal protocol pivotal trial debate passage new legislation provide primary datum regulatory animal extremism united states approval base internal assessment issue relate patient safety arise product development programme market gsk corporate responsibility report corporate responsibility report audit clinical trial ensure conduct training auditing appropriate standard train clinical trial audit clinical trial provide training ensure clinical trial clinical trial outside western europe perform high ethical quality standard north america audit conduct clinical trial ensure clinical trial place western europe carry accord study protocol gsk north america gsk starting perform standard operating procedure sop good trial region central eastern europe clinical practice gcp current regulatory directive south africa latin america parts asia law guideline ethical consideration seek conduct clinical trial declaration helsinki population relevant scientific employee involve design conduct question result monitor gsksponsore trial train gcp generalise broad population train mandatory employee complete require training start qualified investigator capable change job carry research training activity relate people qualify participation gcp training activity represent research successful completion elearne module research carry quickly instructorle course relate gcp efficiently possible employee contractor gsksponsore clinical trial conduct detailed training record ethical standard irrespective routinely request regulatory authority location study meet international national undertaking inspection assess competence regulatory legislative requirement employee undertake clinical trial conduct accordance principle gsk internal audit department audits gsk system good clinical practice gcp standard process involve conduct trial principle contain world medical audit external clinical research association declaration helsinki ethical organisation investigator perform clinical principle medical research involve human research behalf risk management subject gsk policy approach determine trial gsk commit invest rd disease audit risk factor evaluate include disproportionately affect develop country complexity study patient population access medicine compound location study previous audit history usually test clinical trial develop unusual finding conduct study country disease prevalent audits conduct medicine relevant local population audits investigator site conduct gsk leastdevelope country additional sponsor trial represent approximately safeguard need example percent investigator site participate culture comply normal ethical pivotal clinical trial legal requirement additional step take match objective inform consent local audits internal gsk system process culture example local leader andor family manage clinical trial data member need involve consent audits clinical research organisation process carry clinical trial gsk behalf read position clinical trial audits gsk local operating company develop worldin background section include medical department manage website clinical research country cause audits conduct response suspect irregularity investigator report regulatory agency audit result report quarterly rd risk management compliance board annually gsk audit committee concern issue identify audit fully investigate appropriate action take include retrain severe case dismissal individual concern development new training programme procedure prevent reoccurrence trial datum reanalyse gsk corporate responsibility report corporate responsibility report inspection investigator clinical research gsk follow phrma principle organisation independent ethic committee conduct clinical trial institutional review board sponsor clinical communication clinical trial resultsand trial carry regulatory authority commit timely communication result ensure safety trial participant quality product approve marketing datum trial conduct accord possible publish trial result peerreviewe gcp scientific medical journal conference inspection gsk investigator gsk abstract proceeding conduct clinical study research healthcare community obtain late information treatment gsk guarantee publication method discretion journal clinical trial information editor conference organiser reason result launch gsk online clinical trial register supplement prescribing information result clinical trial widely publication scientific literature available healthcare practitioner register contain result protocol use evaluate use medicine information gsksponsore trial market publicly disclose information ongoing trial medicine provide reference publication ongoing clinical trial appear medical journal publicly available internetbased registration use internet access register ongoing clinical trial provide stimulus activity increase participation clinical research end clinical trial provide important reference point interested summary gsk clinical trial register party track subsequent disclosure clinical httpctrgskcoukwelcomeasp include trial result clinical trial major market product gsk legally require post summary protocol complete formation information ongoing study treatment gsk complete lifethreatening disease conduct likely inform medical judgement investigational new drug application continue populate register national institutes health website clinical trial relate market wwwclinicaltrialsgov medicine largely complete addition gsk post protocol summary clinical trial irrespective country involve clinicaltrialsgov end protocol summary actively recruit clinical trial clinicaltrialsgov meet requirement posting set international committee medical journal editor non phase iii trial policy delay post website certain data element exceptional basis competitively sensitive clinical trial result pharmaceutical company legally require disclose relevant data clinical trial appropriate regulatory authority seek approval new product approval sponsor continue obligation provide regulatory authority number summary gsk clinical trial update safety information clinical trial gsk clinical trial register cumulative total patient safety safety efficacy information provide doctor prescribe information year summary approve regulator addition need use way communicate result clinical trial healthcare practitioner use evaluate use medicine gsk corporate responsibility report seirammus fo rebmun approach authorship journal article concern ghost write journal article doctor name article write pharmaceutical company gsk policy authorship acknowledgement article consistent journal guideline determine level contribution study design datum acquisition analysis interpretation writing revise manuscript name senior author paper actively participate drafting process lead content development retain final approval authority manuscript gsk staff contractor contribute development manuscript external author name article read public policy disclosure clinical trial information authorship journal article nnuummbbeerr ooff ssuummmmaarriieess ooff ggsskk cclliinniiccaall ttrriiaallss oonn tthhee ggsskk cclliinniiccaall ttrriiaall rreeggiisstteerr ccuummuullaattiivvee ttoottaall corporate responsibility report genetic research patient objective disclose clinical trial monitor safety safety register trial result new product efficient fully operational worldwide system pharmacogenetic research month product reach market pharmacovigilance maintain study genetic variation disclose result trial complete company dedicate team scientist predispose individual respond product approve marketing year healthcare professional world differently medicine research area potential trial completion small number monitor review evaluate communicate safety improve effectiveness posting delay reason include issue medicine medicine patient safety publication scientific journal identify patient jeopardise safety product assess clinical likely benefit trial product approve medicine independent assessment documentation marketing adverse event occur susceptible sideeffect process procedure gsk approval product large pharmacogenetic rely populate clinical trial register number patient policy analyse dna participant conduct external organisation governance framework place help detect clinical trial result continue engage service organisation act adverse event reasonably treatment collect ensure gsk complie policy associate product drug safety blood sample potential dna procedure establish fulfil governance framework analysis majority phase ii iii drug commitment information clinical adverse event record global safety development trial include research activity available public database clinical trial database investigate ethic committee review clinical pharmacovigilance team approval inform patient consent help monitor balance benefit risk seebenefitrisk management patient safety appropriate respond safety issue ensure patient safety extremely important change product label communicate safety medicine vaccine doctor case action medical device seriously sufficient small number case conduct risk minimisation activity clinical safety medicine trial certain case appropriate medicine modern life ideal stop clinical trial withdraw medicine world medicine target disease market collect report safety disorder mean datum unfortunately despite good effort scientist medicine exist gsk invest number area emerge science potential improve patient medicine potential risk benefit safety example pharmacogenetic research take medicine sidebar experience effect important identify evaluate minimise safety concern enhance pharmacovigilance system ensure overall benefit medicine science pharmacogivilance continually outweigh risk know evolve provide new way enhance pharmacovigilance pharmacovigilance framework benefit industry regulator healthcare professional monitor safety medicine importantly patient enhance pharmaceutical industry major role pharmacovigilance gsk recommend manage safety medicine initiative undertake increase collect investigate proactively evaluate quantity quality report possible information relate effect medicine effect medicine healthcare purpose protect patient professional patient advise drug safety focus development fulfil legal obligation regulatory electronic patient record permit authority report individual adverse real time access anonymise data event aes expedite basis andor detection evaluation possible effect periodically accord drug safety regulation country pregnancy registry establish health care system enable rapid collection strive ensure patient interest serve evaluation datum relate possible adverse prompt detection potential safety issue event include birth defect drug appropriate communi cation regulator occur follow evaluation research undertake establish decision action take effective way minimise risk medicine collect report safety datum include effective way communicate benefit risk medicine healthcare professional patient gsk corporate responsibility report corporate responsibility report increase harmonisation pharmacovigilance rule rapid consistent implementation ich guideline eu japan eu pharmacovigilance regulation introduce streamline simplify pharmacovigilance reporting requirement europe order achieve necessary industry regulator work safety monitoring consider competitive area benefit party carry high standard gsk make new idea technology available pharmaceutical company regulator present scientific conference work party software supplier new advance accessible gsk corporate responsibility report corporate responsibility report ethical conduct gsk commit business practice meet high standard ethical legal compliance ensure employee behave honesty integrity get right require combination effective system ethical corporate culture understand require conduct business honesty integrity compliance applicable legal requirement find patient consumer doctor government management certification business ethic report want use medicine company commitment code conduct reinforce ethical issue rd trust reputation annual management certification programme include policy stakeholder critical business require manager confirm comply relationship doctor meet high ethical standard enable ethic policy programme cover involve clinical trial maintain support retain licence manager worldwide eligible manager disclosure clinical trial operate help attract retain business unit complete certification result write motivate good people article medical journal unethical conduct legal certification manage electronically non relationship financial consequence company certification track follow non government patient ethic programme important element certification typically extended leave group risk management good stewardship absence maternity leave longterm sick supply chain standard corporate asset leave access medicine section explain approach business certification statementis reproduce policy market ethic progress embed background section website website ethical culture gsk cover business ethic supplier background gsk code conduct management expect supplier operate high information ethic certification business ethic ethical standard employee policy supply chainpage code conduct marketing ethic include code practice policy directtoconsumer european marketing advertising code practice ethical training awareness programme market ethic monitor compliance system include gsk market medicine doctor hospital channel report case misconduct government countrie datum number employee dismiss advertise medicine directly consumer discipline violate company policy specialist sale representative meet regularly doctor pharmacist inform medicine approve use code conduct believe sale representative play important role provide uptodate information employee guide business conduct require doctor product benefit employee act integrity comply patient recognise marketing law avoid conflict interest report pharmaceutical product raise challenging violation law gsk policy issue unethical behaviour provide guidance include particular people concern specific example constitute acceptable marketing pharmaceutical company exert unacceptable behaviour undue influence doctor sale employee learn standard representative doctor induction access guide company information potential effect intranet promotion unapproved use common despite increase training monitoring read code conductand employee guide oversight business conduct gsk corporate responsibility report corporate responsibility report promotion pharmaceutical product highly marketing code regulate government extend strengthen policy grant practice summary legislation area instance state independent medical education grant accurate information information require pharmaceutical company restrict new center medical education provide approve use report interaction doctor requirement corporate ethic compliance medicine vary prohibit company provide department grant medical education base valid scientific meal set annual spending limit require company mecs hospital medical association evidence transparent report similar legislation patient group account accurate balanced fair consider state american percent organisation annual budget objective unambiguous uptodate medical association enable doctor request sale staff permit deal mecs prescribing activity share provider independent medical education promotional item pharmaceutical company recommend speaker education healthcare professional promotional item programme approach address issue include give occasionally follow international region relevant practice medicine revise marketing code gsk employee comply nominal value international region ensure meet new ifpma marketing code practice revise strengthen policy standard add comprehensive qa help item employee understand requirement inducement prescribe govern consumer advertising provide guidance employee use medicine medical sale marketing employee receive training healthcare professional consultant professional retain consultant gsk ensure good understanding sponsorship healthcare professional attend marketing policy legal framework conference appropriate hospitality govern sale activity meeting entertainment europe permit hospitality programme monitor compliance update gsk european promotion travel cost food include region feedback medicine code practice march ensure provide meeting doctor sale practice alignment update efpia code major educational purpose level hospitality change include marketing code practice appropriate pharmaceutical marketing promotional new section distribute product occasion provide relevant activity policy apply employee agent information healthcare professional healthcare professional commit promotional practice email internet spouse child office ethical responsible principled patientcentred prohibiting use competition prize personnel prohibit kickback bribery inducement guest travel cost promote medicine doctor promotion unapproved use provide medicine establish new procedure relationship decision grant patient group commit publish medical education policy support regional marketing gsk funding group patient review qualified medical practice code europe international region advocacyon scientific personnel japan code apply compliance function ethical standard reflect difference market rd structure national healthcare system strengthen rd policy gift regulation incorporate principle entertainment policy state primary industry code practice efpia ifpma purpose meeting facilitate jpma phrma marketing code substantial discussion medical scientific topic meal provide meeting code available language incidental meeting meal employee access intranet modest value gsk personnel copy gsk european promotion present medicine code practiceis available consumer advertising website section explain approach advertising progress prescription medicine revise procedure make charitable consumer healthcare product market donation healthrelate organisation directtoconsumer advertising fund external science medical programme advertise prescription medicine region decision grant consumer tv print advertisement relevant medical andor know directtoconsumer dtc compliance personnel sale advertise new zealand bangladesh korea marketing department allow limited dtc advertising dtc advertising prescription medicine permit market gsk corporate responsibility report corporate responsibility report support industry implement policy incorporate belong consumer healthcare product code conduct new phrma guiding principle dtc association comply code gsk support effort advertising prescription medicine state advertising practice nonprescription strengthen marketing standard dtc advertising medicine state advertise pharmaceutical imply casual attitude medicine industry include begin spend appropriate suggest overthecounter medicine global help revise time educate doctor prevent cure disease international federation healthcare professional new medicine treat licensed practitioner addition gsk pharmaceutical manufacturer association ifpma code design educate consumer policy require claim advertisement pharmaceutical marketing medicine condition consistent product label advertising practice gsk member prescribed compare gsk product competitor newly form code support adequate datum compliance network accurate support evidence support implementation gsk consumer healthcare advertising review include information risk benefit ifpma standard copy review committee large market train education gsk treatment medical legal personnel smaller helped revise european provide information treatment option market publication ensure meet federation pharmaceutical industry association efpia diet lifestyle change standard code practice promotion reference prescribe information overthecounter medicine promote medicine product pharmacist doctor dentist sale greece gsk greece lead reminder advertisement short advertisement team prescription weight loss medicine local industry body work mention pharmaceutical brand promote preparation approval group set improve medical condition design treat overthecounter medicine consumer local code practice permit healthcare medical sale team complete online korea gsk lead effort training marketing code practice prior improve korean research dtc television advertisement include audio promote product base pharmaceutical industry visual component submit association code conduct food drug administration fda review advertising child endorse day advance problem gsk guideline advertising child meet korea fair trade commission dtc advertising identify fda exceed local law code practice japan gsk join executive prohibit advertising design appeal steering committee fair target child legally mandate trade council ethical member public healthcare professional pharmaceutical drug send comment dtc advertising phrmas minimum age example uk manufacturing industry buy advertising space children medium office accountability establish seeks strengthen compliance supply vend machine primary school forward relevant company office marketing code accountability report periodically sport star sponsorship important brand slovakia gsk general comment company response lucozade sport guideline state manager slovakia help fda gsk receive comment people set appropriate example find recently form local industry association office accountability dtc sponsorship lead group advertising appeal solely child age sri lanka gsk lead effort employee involve dtc marketing create marketing code attend train new policy phrma sri lanka chamber principle develop dtc elearne pharmaceutical industry base ifpma code module future training disease awareness campaign fund disease awareness campaign design increase understand specific disease link promotion gsk product revise policy clear disease awareness campaign imply endorsement government agency professional body patient advocacy group consent campaign include link party website permission website contain information use product outside licence nonprescription product advertise overthecounter medicine oral healthcare nutritional product directly consumer govern national regulation code practice advertising generally stringent requirement prescription medicine gsk corporate responsibility report corporate responsibility report training awareness view directtoconsumer new sale marketing staff advertising training awareness programme help complete train exist promote use prescrip employee understand comply ethic staff receive hour annual refresher training tion medicine directly consumer controversial policy compliance formal performance critic believe encourage global leadership survey percent objective sale marketing employee people request unnecessary manager say believe people appraise follow objective treatment add burden healthcare systems department commitment performance integrity consistently follow company policy believe responsible procedure complete require compliance pharmaceutical advertising specialised training provide employee train timely manner report compliance useful source health working rd manufacturing sale issue manager legal compliance information patient market additional regulatory helps increase knowledge requirement addition manager evaluate condition educate follow objective patient treatment monitor success training option regular employee survey survey ensure supervised employee train country district sale manager dsm play company policy procedure take dtc advertising important role help sale representative require training provide oversight common industry practice resolve compliance question show direction supervise employee need ensure product substantial majority dsm good compliance company policy promote way understand compliance issue procedure gsk disadvantage confident help representative resolve launch compliance university competitor grey area survey identify opportunitie sale manager day programme patient consult enhance training resource material design improve understand policy physicians instance provide manager additional ability manager guide staff reduce condition appropriateness training material increase expertise number breach policy increase prescription medicine provide effective guidance staff manager expertise detect compliance issue obtain consent receive medicine ethic train corrective action take early new employee uk complete international induction training code conduct sale marketing staff continue ensures understand importance receive training pharmaceutical international ethical conduct day know deal promotion marketing code involve initial dilemma seek help awareness session induction course regular run ethical decision make workshop reminder refresher facilitate medical staff manager hot topic train sale conference programme follow email send addition number supplemental policy encourage manager review key point implement add team pilot elearning module internal intranet community support ethical leadership corporate hr visibility international staff training sale corporate ethic compliance team marketing staff deliver half roll manager worldwide update international code europe training awareness sale pharmaceutical sale marketing staff marketing europe train update promotion employee work sale marketing receive medicine code practice certify extensive training ethic marketing understand revise code policy include ethic training rd induction train new employee update performance integrity face marketing code practice toface induction training rd employee sale employee require pass test complete new exist marketing code start sale employee worldwide mandatory role course offer language include train code conduct conflict interest detailed training sale representative acceptance gift entertainment medicine promote disease employee external professional activity design treat regular refresher course hold year yearly bulletin major type unethical conduct detect action take employee senior manager european region receive quarterly update number type disciplinary action policy breach gsk corporate responsibility report corporate responsibility report launch additional training rd employee monitor policy govern compliance collection use storage protect recognise strong policy code practice medical information information hold good training guarantee clinical trial participant relate health employee meet standard internal status medical condition compliance system design identify collection use human biological address breach code sample datum integrity management human section cover safety information role corporate ethic public disclosure clinical trial result compliance department posttrial treatment participant gsk channel employee report concern sponsor clinical trial suspect case misconduct ethic training practice address misconduct ethic training design help employee apply policy real life situation right number employee dismiss decision work discipline misconduct example employee encourage ask corporate ethic compliance function follow question make corporate ethic compliance department decision promote effective compliance programme address compliance issue report problem embarrassed friend family progress senior management board know decision dedicated compliance officer decision look cynic business unit rd manufacturing newspaper headline look like biological pharma europe international pharma consumer healthcare japan pharma confident right decision pharma addition corporate compliance gsk officer report directly ceo training employee explore ethical dilemma compliance officer senior manager direct face work receive guidance access leadership team gsk function help understand appropriate response source expertise example recent training session question ethic gsk policy european scenarioyou trade conference international region support business card prize draw win network regional country compliance officer grand prize set golf club worth local compliance champion enjoy golf like new set strengthen network particularly club draw sponsor exhibitor eastern europe gsk business sale representative supervise club manager regularly monitor educational guidance take account gsk policy event visit doctor expense acceptance entertainment gift gsk independent monitor review record employee club accept number key risk area internal well business card audit department regularly audit sale draw marketing practice globally objective gsk require business functional unit translate key policy employee identify significant risk implement effective guide business conduct language control manage risk periodically review improve understanding business risk provide upward communication significant issue arise create company wide compliance training employee guide business conduct supplement local training reinforce sale marketing annual management certification business compliance adviser provide feedback ethic infraction conduct customise training recommend process improvement important link compliance department commercial unit compliance datum analysis reporting function coordinate monitor report target compliance effort gsk corporate responsibility report corporate responsibility report set strategic tracking analysis address misconduct report star system give senior manager corporate ethic compliance department access comprehensive compliance information monitor track allegation suspect case make easy identify instance non legal ethical policy infraction ensure compliance area appropriate allegation appropriately investigate action disciplinary action include dismissal take necessary europe european code marketing practice include discipline reporting process change quarterly reporting mechanism market order provide gsk ability confirm breach code well identify issue result formal hr practice occur severity breach disciplinary action significant change include new action take prevent category section precise reporting direction recurrence report review senior interactive training session conduct manager expense payment doctor appropriate personnel example speaker fee monitor locally improvement information policy summary report market review discipline case differ information european compliance officer quarter report previous year overall level dismissal collect similar previous year international directly comparable future report gsk establish monthly review system hr policy discipline number international region senior manager baseline compare policy review resolve number compliance discipline trend issue mechanism minor issue resolve local level reporting channel employee discipline policy employee encourage seek help violation report concern suspect case dismiss agree leave misconduct line company voluntarily know separation management compliance officer confidential integrity helpline offsite post office disciplinary action include document box warning instance financial penalty report channel promote employee stay company receive employee guide business conduct gsk retrain increase monitor intranet training disciplinary action include case employee breach sale marketing code case result dismissal contact compliance function separation company increase case result document warning datum analyse compliance trend percent employee regional difference identify appropriate seeking advice information percent corrective action employee report suspect case misconduct compliance group continue effort promote high standard legal compliance ethical behaviour use integrity helpline compliance resource yearonyear growth percent percent see contact figure great awareness sensitivity standard doctor raise concern report unethical conduct gsk sale representative customer response centre market research industry association phrma abpi staff train deal concern marketing practice raise healthcare professional patient public redirect call appropriate senior management compliance officer necessary gsk corporate responsibility report corporate responsibility report employment practice goal good place good people well work central business strategy underpin success people great source competitive advantage skill intellect essential gsk discover deliver good new medicine vaccine successfully market selling prescription consumer healthcare product employment gsk employ people gsk spirit awards gsk country goal company work mother expect employee meet high standard talented people apply energy good place work way carry work gsk gsk passion difference world britain employer spirit define culture principle competitive reward important independent survey run expect employee work include factor influence ability recruit retain corporate research foundation guardian talented employee performance integrity newspaper rank th section explain approach employment innovation entrepreneurial spirit britain admire performance include company accountability achievement management today rank initiative increase diversity inclusion passion sense urgency th training development talent management good company work continuous learning development awards germany internal communication communi regular performance appraisal assess hungary ireland mexico cate employee feedback russia employee uphold principle flexible working arrangement wellbeing requirement code conduct work human right campaign resilience programme support healthy ethical conduct code good place work gay lesbian bisexual workforce result affect bonus career progression transgender employee gsk breakdown global employment business end receive perfect score december employee survey business number function employee regular employee survey help monitor gsk maufacture culture gauge employee satisfaction assess effectiveness employment policy sell global leadership survey gls send gsk rd manager year available adminisration language manager take percent response rate survey track total view previous survey finding global company crosscompany database database include topranked company industry include pharmaceutical automotive banking energy normative database response million employee country gsk corporate responsibility report corporate responsibility report key survey finding survey show manager gsk satisfied company manager company take gsk participant satisfy overall response average percent high industry gsk gsk gsk benchmark favourable favourable favourable overall satisfaction gsk people department commitment performance integrity na proud gsk people department commit enable meaningful contribution na report unethical practice fear reprisal work expect right gsk company great people well work na satisfied recognition receive good job sufficient effort opinion think people work leader department act teacherscoache champion development na receive ongoing feedback help improve performance diversity inclusion improvement plan survey result review corporate aim create inclusive working environment executive team identify key area gsk employee diverse background focus flourish reduce unnecessary bureaucracy diversity benefit business workforce business diverse background culture outlook help well understand need different leadership visibility define drive patient customer deliver genuine manager spend time team equality opportunity sure visible respective good people right job business reinforce commitment diversity business unit function develop inclusion di action plan address area improvement corporate executive team endorse global policy di support activity initiative annual multicultural marketing diversity award companywide di policy practice available view employee intranet monitoring report datum gender diversity management grade worldwide ethnicity uk gsk corporate responsibility report corporate responsibility report reinforce gsk spirit state ethnic diversity value draw differ knowledge minority define black hispanic perspective experience style resident asians pacific islander american indians global community alaskan native percent workforce compare percent di steering team uk run percent average awareness campaign train close comparator chemical industry employee diversity champion business unit field staff employee network provide insight support diversity objective background information approach di available website conduct annual survey employee select random gauge progress inclusion resilience survey achieve percent response rate percent agree workgroup climate diverse perspective value percent agree manager demonstrate ability manage diverse workforce uuss mmiinnoorriittyy gender diversity uk ethnic minority define uk gender diversity management commission racial equality cre account worldwide percent employee compare woman position percent percent cre management grade hold woman define ethnic minority identify white british figure census percent population ab bands england wale ethnic minority c c c c total management grade corporate executive teamsenior vice president vice president director grade manager grade positive trend increase female representation management position reflect impact gsk di strategy business effect flexible working policy uk ethnic minority attract retain woman support di survey percent employee agree manager alternative measure diversity number enable flexible innovative solution employee define non manage work personal life white percent gsk uk employee define nonwhite compare year annual woman percent percent science event foster positive mentoring relationship gsk female age scientist female student aspire enter advance new age discrimination regulation science field expose student handson uk carry comprehensive review reallife laboratory research environment policy practice consult uk enhance gsk ability attract retain information consultation forum result woman field science number policy amend update extensive training provide hr professional change communicate manager employee ensure understand implication new law gsk corporate responsibility report corporate responsibility report disability commit offer people leadership training include disability access range recruitment manager attend leadership edge career opportunity gsk uk programme award tick symbolfrom jobcentre plus partner employer forum manager attend inspirational disability interest group ensure leadership workshop focus inspiring disability confidentorganisation motivate people high performance multicultural marketing diversity manager attend new manager award experience manager training annual multicultural marketing diversity manager attend hot topic award fifth year inspire staff find harness power real conversation creative way reach wide audience employee customer community manager attend hot topic art self leadership award give category include employee attraction development retention development multicultural marketing sale community regular performance appraisal reward strong outreach diversity ambassador performance identify training need help entry award employee set objective align employee receive gsk diversity business priority twothird gsk ambassador award lead diversity effort employee receive annual performance appraisal passion innovation impact performance development planning pdp programmes employee network employee network integral di pdp include assessment employee programme network support professional growth implement gsk spirit principle participate employee provide forum use define culture impact employee similar background meet bonus payment affect future career discuss issue share concern development network particular diversity focus employee turnover include network asian african american number team focus issue hispanic gay lesbian bisexual transgender affect employee retention example employee benefit participant management people different age group network act source expertise diversity development promotion female issue people gsk minority employee employee network executive sponsor reward strong performance help set achieve goal obtain performance relate pay share ownership resource promote network objective scheme help attract retain good people senior management gsksponsore generate culture ownership network regardless affiliation open employee country employee share gsk employee ownership scheme exist level participation high talent management talent management process help identify employee development develop leadership candidate identify talent management high perform employee business function annual talent management gsk invest train development enable cycle talented individual leadership employee perform good ability programme expose management support career progression work programme chief executive hard attract retain well bright forum people gsk help develop potential training provide jobrelate training course employee leadership training manager employee enrol training programme mylearne intranet site available uk country register system course completion gsk corporate responsibility report corporate responsibility report internal communication good internal communication important similar forum country achieve business objective create national practice open inclusive work environment communicate corporate responsibility range communication channel employee employee date company news responsible business policy practice enable feedback communicate outside world employee include important stakeholder right want know progress mygsk global intranet site provide news responsibility issue update qa section employee question directly employee inform corporate ceo senior executive jp garni responsibility regular news article gsk chief executive answer question gsk intranet article spirit magazine employee news section presentation departmental group gsk intranet give company position summary cr report distribute important issue link press story employee gsk webbroadcast gsk senior manage ment include executive team member employee major employee health site protection promotion wellbee spirit internal magazine reach employee ethical obligation important employee company contributor goal employer choice time year site produce local philosophy support business strategy newsletter healthy resilient workforce drive confidential feedback mechanism enable positive business performance increase employee raise concern include employee productivity attendance healthy integrity helpline ethical conduct worker reduce health care insurance cost regular employee survey healthy high performance healthy culture townhall session consider dimension health vitally employee level company important high performance physical emotional host senior management employee mental spiritual people need physically opportunity discuss progress energise emotionally connect mentally focused business raise question feedback spiritually alignedmeaning sense track effectiveness communication purpose link dimension employee survey monitor factor enable high performance question employee senior manager factor range fitness nutrition self qa page mygsk ensure awareness time management deliver pick potential area concern track programme corporate athlete readership news story mygsk help health risk assessment hra direct improve relevance interest content improve factor measure risk reduction health impact employee consultation consult employee change affect drive healthy culture gsk start europe discuss business development leadership want company leader european employee consultation commit continuous development forum eecf eecf receive update physical psychological gsk global business leader review effective leader role model proposal progress report number employee european initiative distribution medical resilience national consultation forum use term resilience describe skill establish uk information behaviour need successful highly consultation forum provide information pressured environment set skill company progress plan help helps prevent workrelate mental illness stimulate constructive dialogue employee leading cause illhealth lead time representative uk forum away work resilient employee manage elect employee representative work home demand effectively minimise seven manager meet time year adverse health affect stress date review area employment policy change uk pension arrangement preparation support employee event flu pandemic gsk corporate responsibility report corporate responsibility report identify manage challenge develop new global management role employee resilience mental focus improve health employee accordance gsk global resilience mental world develop health standard majority gsk site resource share good practice programme reduce workplace pressure help employee achieve good worklife balance develop health risk appraisal tool time management training flexible working site option health awareness work relate mental illhealth percent work world heart federation joint project site india team resilience programme available ground break threeyear study look language help gsk team control different intervention aim reduce work avoid excessive pressure effect chronic disease identify lead stress step assess seven source effective intervention sustainable pressure impact performance transferable company health identify extent pressure team community programme face team member consider issue create excessive pressure begin global health education webinar web manage effectively objective base seminar avoid pressure help ergonomic achieve high performance avoid reduction musculoskeletal illness injury strain overwhelmed excessive work continue key area focus demand lead cause time away work end people set target reduce number team go prog illness injury percent year ramme result significant improvement well workplace job design science year programme call ergonomic prevent musculoskeletal injury illnesse increase efficiency report pressure worklife conflict fall productivity percent ergonomic improvement team include cross participate staff satisfaction increase functional team member impact work percent work environment design percent increase willingness staff implement establish experiment new work practice ergonomic improvement team manufacture site world ergonomic team take profile second workshop provide region uk time show improvement seven france india malaysia increase inhouse source pressure percent ergonomic knowledge expertise percent site share good practice work range provide training programme support commercial operation laboratory research personal development help individual manufacture intranet site call global resilient pre postassessments pilot ergonomic community intranet site provide employee find improvement access late information ergonomic element measure great good practice validate tool practitioner improvement employee sense relaxed include online computer ergonomic risk engage month number assessment tool online assessment people feel pressured rise fifth gsk site globally employee personal health worldwide tool past programme aim improve health year assess computer work employee family benefit step need improve workstation business increase employee commitment ergonomic principle integrate design productivity reduce cost illhealth include major engineering project furniture support include onsite health fitness centre procurement take ergonomic consideration flexible working arrangement family support ensure appropriate furniture equipment service healthcare benefit focus prevention select access innovative prove treatment hiv example employee receive free provide antiretroviral treatment hiv immunisation cancer screening help smoke positive gsk employee parttime cessation regular check up assist family country treatment employee suffer chronic disease available adequately consistently medical plan continue treatment local healthcare system background information employee access antiretroviral drug gsk corporate responsibility report corporate responsibility report develop awarenessraising material programme cover wide range health use peer educator project fund safety hs aspect provide safety training positive action deliver national aid sale employee work employee trust gsk employer use material improve general health section report deliver training way address problem specific health safety issue hiv aidsrelated stigma environment section information manage environmental material base experience gsk broad ehs issue kenya adapt version india central america french version promote gsk foundation francophone africa health safety flu pandemic preparedness management gsk commit support government health authority world manage health safety employee minimise impact integrate environment health safety eh global influenza pandemic management system system incorporate ehs employee health policy eh vision gsk play vital role provide potentially life global ehs standard ehs plan save medicine vaccine flu excellence set strategy improve ehs continue produce critical medicine performance renew plan invest billion expand extended ehs seasonal flu vaccine capacity develop avian management systemin background page flu vaccine increase production capacity antiviral flu treatment relenza ohsas certification contribution society additional site achieve certification international health safety standard develop plan ensure ohsa bring total number continuity critical business operation manufacturing site certify process safeguard health gsk pharmaceutical consumer manufacturing employee dependent key contractor site certify site argentina china site gsk market develop egypt france germany india japan kenya comprehensive country plan cover local mexico poland saudi arabia turkey usa business unit plan include annual seasonal uk voluntary certification process flu vaccine travel health programme measure replace plan require manufacturing reduce infection risk work management site certify sickness absence provision treatment course antiviral possibly vaccine training awareness employee immediate family member train target match employee worldwide market expect responsibility employee responsibility complete plan quarter hs issue receive regular training initiative area ergonomics chemical exposure driver safety handle regional meeting hs staff turn train employee manufacture research sale health safety division corporate ehs employee health staff work arrange annual meeting determine training issue provide training material health safety employee contractor absolute priority gsk want employee aware health programme systematically assess risk safety personal life employee bulletin associate operation monitor announcement myehs website ceo performance aim learn cause ehs excellence awards programme health incident action protect employee safety week activity aim raise employee workplace awareness issue wear seat belt careful electricity ladder ultimate aim eliminate workrelate appropriately injury illnesse ii focus reportable incident conduct health safety week aid necessarily result time work october coincide european health lose time main measure safety week fire safety awareness month performance past believe united states information kit send addressing cause minor event help site help develop idea plan activity eliminate risk hazard lead employee site fewer reportable case losttime ii case country take health safety new target reduce reportable week activity include safe drive education ii percent year monitor training fire evacuation ergonomic aid report lose time incident long awarenessraise noise healthy eat target measure lifestyle gsk corporate responsibility report corporate responsibility report excellence awards risk assessment guideline revise employee health management chief executive officer environment health align risk assessment requirement uk resilience policy safety ehs excellence awards recognise quality group employee health management develop wideranging reward innovation gsk site win entry self audit train workshop self resilience policy successfully eh initiative health safety category auditing conduct ehs network meeting address worklife balance feature pressure issue benefit management system element agreement gsk employee ceo ehs excellence award global manufacturing supply target define resilience ability award programme winner previous ohsa certification iso successful personally year employee health professionally high certification pharmaceutical resilience pressure fastpaced consumer manufacturing site continuously change environ ment policy encompass team resilience process personal resilience workshop ehs audits focus work home injury illness rate balance fulfillment aim conduct ehs audits operational cause project global site year carry application focus frequent visit select site depend main measure injury illness number year uk assessment risk issue raise previous reportable case require site report second year audits express rate hour work programme project offer globally auditor signal critical finding conclude target reduce reportable injury currently active india japan high probability incident illness rate percent year end china brazil argentina finland potentially consequence czech republic nigeria finding involve israel reach deficiency measure number day lose employee injury illness provide indication project place control exposure high hazard chemical severity incident ehs initiative health agent rough guide example illness lead safety category ceo ehs manage dust explosion risk relate dust permanent hearing loss disability excellence award collector result significant lose time manage fire explosion risk main datum cover gsk employee contract flammable liquid worker directly supervise separately report datum contractor work gsk preventing fall elevated location site supervise staff contractor datum site action monitor ensure covered sgs verification datum appropriate action take mitigate collect pharmaceutical risk ensure ongoing compliance consumer manufacture site critical finding delinquent great biological manufacture site pharma day overdue ceutical consumer research development site major office location small actively track audit finding identify office improvement followup audits site score percent provide cause injury illness increase support audit team include injury lose time arise mainly followup visit ensure progress discussion slip trip fall overexertion strain senior business management increase motor vehicle accident site resource site require year losttime illness stem mainly mental illhealth adequate system programme place musculoskeletal problem primarily repetitive area strain injury musculoskeletal illness main introduce continued specific work cause reportable illness lead follow area achieve improvement day work account total chemical agent monitor determine exposure ensure adequacy respiratory highlight protective equipment require site country losttime unit operation engineering injury illnesse year addition control implement site india achieve million hour resilience rollout tool assess work losttime injury illness team resilience training ehs network site india achieve million hour meeting work losttime injury illness ergonomic train ergonomic risk site achieve million hour assessment network meeting work losttime injury illness regional training gsk corporate responsibility report corporate responsibility report performance site argentina canada india year trend employee fatality record injury philippine singapore spain sri lanka uk illnesse total achieve million hour work fatality incident compare losttime injury illness respectively employee lose working day reportable injury illness rate percent incident gsk injury illness target performance place quartile benchmark industry group mean need improve baseline work time lose investigate circumstance fatality injury illnesse rate lose time injury incident assess illness hour learn reduce risk issue global work alert post intranet site communicate injury baseline information help prevent similar incident illness lose time site rate injury illnesse lose time hour work injury illness hour work target lose calendar safety programme day injury calendar day lose illness systematically assess risk anticipate potential rate calendar day lose hour work reportable injury illness rate accident programme place minimise year ii hour learn investigate cause data table detail accident improvement accordingly section cover key area driver safety process safety material hazard information chemical exposure driver safety sale representative drive long distance year particularly risk incident involve workrelate road traffic incident fatality drive accident result fatality result lose time fatality account percent losttime injury november employee contractor die result injury suffer explosion compliance tool driver call ehs fire cause ruptured butane cylinder essential include instruction guideline cook canteen agbara nigeria driver training vehicle selection risk assessment consumer healthcare factory thorough accident report information investigation conduct global audit continue use implement driver safety team improvement identify progress programme world implement improvement monitor third gsk commercial business audit team learning incident extensive driver safety programme place share gsk include drive licence check guidance april sale employee india die result use mobile phone vehicle driver safety head injury suffer motorbike training tracking reporting incident collide motorbike work ensure site high standard place irvine explosion concentrate improve area accident explosion occur irvine uk site injury reporting driver training february involve placebo batch test plant condition control operator country provide motorbike injure event thoroughly scooter employee produce gsk investigate learning share improvement motorbike rider safety manual uk regulator hse consider translate distribute employee country course action prosecution possibility bangladesh india indonesia pakistan vietnam country fully amputation implement gsk requirement driver incident involve gsk motorbike wear helmet continue employee result partial finger follow monitor implementation amputation cause work equipment motorbike safety programme gsk corporate responsibility report corporate responsibility report process safety source percent unit operation process safety programme ensure safety handle high hazard compound build manufacturing research employee need wear protective development process programme base equipment hazard identification control risk substantial progress assessment recruit number regional launch major review process safety hygienist deliver improve occupational strategy follow explosion hygiene service business world irvine factory encompass establish baseline performance consistency design standard develop deploy evidence basis safety include business tracking tool monitor progress gap documentation installation check respirator free completion chemical risk assessment skill competency process safety enhance collaboration control change nonroutine operation engineer occupational hygienist culture issue awareness attitude level ensure control solution behaviour implement material hazard information revise update guideline focus preparation new business control measure legislation significant impact begin build occupational assess communicate material hazard hygiene network bring specialist information continue publish ehs hold network meeting information key product safety datum occupational hygienist ensure common sheet pharmaceutical approach understanding consumer healthcare product sell business europe available website safety datum sheetsfor information engage new product introduction team ensure new alternative animal testing installation meet respirator free standards occupational toxicology programme example assess chemical approach occupational potential cause skin andor eye irritation hygiene control chemical exposure workforce assessment conduct background page use laboratory animal information chemical structure novel human tissue test occupational toxicologist information establish workplace exposure limit unique gsk material support commitment ensure product adversely affect environment pharmaceutical environment enhance environmental hazard testing programme include number new study aim assess long term effect aquatic organism addition new eu technical guideline conduct extensive environmental testing new drug substance occupational hygiene control chemical exposure exposure chemical result respiratory skinrelate losttime incident case result lose time account percent workrelate illness develop strategy control chemical exposure set plan achieve respirator free status validate control gsk corporate responsibility report corporate responsibility report supply chain supply chain complex supplier worldwide range major strategic relationship supplier manufacture active pharmaceutical ingredient intermediate raw material packaging gsk medicine local contract good service office equipment clean security gsk supply chain endeavour ensure supplier selection gsk manufacture sell supplier follow high standard critical supplier pass detailed assessment diverse range product gsk regard environment select look mean source wide health safety ehs loss prevention human quality assess policy procedure range supplier example right give size global scope supply health safety human right environmental product agricultural chain challenge recognise issue include use questionnaire source material supplier meet standard supplier site review quality audits ehs audits facility blackcurrant milk performance directly supply gsk petrochemical complex chemical compound work supplier issue contract manufacturer approve active ingredient approach include applicable regulatory authority pharmaceutical start manufacture gsk medicine volume high volume preassessment start work tailormade package new supplier plastic low volume inclusion human right ehs requirement raw material flavour supplier contract service supplier supplier contract temporary worker cleaner review ehs human right routine research company supplier engagement eh professional advisor supplier contract contain requirement base buying service eh supplier audits global ehs standard provider start outsource service previously supply base large complex human right manage inhouse possible engage directly supplier supplier contract contain human right clause issue focus critical supplier base international workplace norm critical supplier contract manufacturer international labour organisation convention supplier present great risk gsk uns universal declaration human right follow issue read human right clause background section website threat continuity supply new local central supplier contract hazard associate manufacturing worldwide include human right clause process material add contract exist supplier environmental impact renew contract renew threeyear cycle vast majority contract regulatory requirement include clause relevance supply essential medicine engagement auditing supplier base primarily europe north provide contract manufacturers america asia account approximately information eh risk associate percent total supplier spend gsk material produce handling expect critical supplier work high inform supplier ethical requirement standard produce uninterrupted supply policy supplier booklet working material service gsk gsk include ethic policy explain safety effectiveness availability medicine gsk employee prohibit accept gift affect reason important entertainment supplier ask respect forge longterm relationship position apply standard undertake regular monitoring assess progress business interaction gsk allow intervention necessary country send letter supplier local festival season make aware policy ask refrain send gift provide entertainment gsk corporate responsibility report corporate responsibility report consider ehs human right issue eh acceptability criterion key supplier routine interaction critical supplier contract manufacturer score percent interaction include ongoing supplier review ehs quantitative audit scheme ehs followup visit procurement quality ehs performance identify unacceptable staff hold global regional supplier percent progress require ehs risk review meeting senior gsk manager impact consider manage robustly address interact supplier key issue site consider acceptable supplier contract manufacturer start pilot project assess risk human right issue occur wide range performance note supplier service decide focus site audit range audit score follow area supplier percent percent supplier fail meet percent ehs supplier outsource business process acceptability criterion company start work supplier india progress supply work include provider outsource service underway ensure improvement example account payable department manage indian supplier provider ehs audits human right issue technology professional service significant concern note grow important area focus training gsk procurement team ensure select right supplier important employee understand strong reputation employee satisfaction standard provide training procurement research show supplier work staff source group management typically lead way survey good indian programme explain develop source business process outsource employer strategie criterion supplier selection supplier promotional gift item include human right ehs train gift item source indian compulsory new procurement staff business source india launch new training effective industry high risk use child labour contracting explain requirement implement process unannounce human right clause include supplier spot check supplier contract compulsory procurement night result spot check staff expect complete agree corrective action supplier training end improve standard area report supplier ehs performance ehs audits try collect ehs datum key supplier conduct regular environment health safety past year limited audits critical supplier contract manufact success supplier collect datum urer pharmaceutical consumer healthcare use manage ehs programme product priority undertaking audits base identify impact specific manufacture business ehs risk include factor relate gsk product datum receive continuity supply hazard present process supplier reliable material regulatory regime essential conduct survey supplier medicine focus high risk request corporate responsibility supplier committee audit committee board quantitative evaluation site determine supplier provide ehs standard protocol acceptance criteria information want understand place site supply supplier impact measure total ehs minimum performance level meet footprint process generate recommendation follow audits product ie gsk supplier facility progress monitor particular focus work ribenasupplier poorly perform supplier performance review wildlife trust improve biodiversity blackcurrant undertaken check progress help drive farm understand overall environmental continue improvement site impact operation case study mean annual visit section website detail supplier performance assessment conduct supplier active pharmaceutical ingredient intermediate material global pharmaceutical supply chain uk europe asia region site supply product material audit uk eu asia south africa gsk corporate responsibility report corporate responsibility report environmental management vision achieve sustainable competitive business advantage environmental sustainability leadership excellence aim reduce environmental impact address broad sustainability issue climate change product stewardship material energy efficiency qa discover develop manufacture sell plan excellence pharmaceutical consumer product launch ehs plan excellencein require significant resource james hagan set strategy improve ehs need understand address report vice president corporate performance tenyear period environmental impact include issue environment health safety review year performance renew common manufacturer use plan second stage extend energy water waste handling need consider potential impact certain chemical release volatile organic begin review plan excellence compound voc chemical extensive consultation key internal inhaler damage ozone layer external stakeholder encourage adopt contribute climate change industry high aspiration align ehs objective specific impact release closely business strategy pharmaceutical environment use year plan establish patient fundamental programme protect employee environmental systematic approach management community environment priority gsk issue crucial control need renew plan include commitment priority manage consistent long term important stakeholder engagement strengthen focus issue properly look people away control emission sustainable environmental practice plant process context longterm strategic plan process develop implement new operational efficiency require new approach process efficient use manufacturing process mean work raw material produce waste incorporate environmental performance gsk form ask operation step environmental sustainability process design move compliance risk worldwide contribute long term goal management add value create new creation selfregulating opportunity example want overall responsibility environmental issue framework programme treat hazardous waste stream ie policy standard guidance rest corporate executive team choose process produce hazardous audit etc define board board champion environment waste believe operate health safety ehs jp garnier chief legal compliance basic executive officer rupert bondy general counsel renew plan design complement foundation identify operational champion ehs corporate business strategy contain ehs key risk gsk employee chemical exposure process safety executive team corporate responsibility aspiration gsk ergonomic driver safety committee corporate ehs department ehs fundamental embed continue work environmental issue manage business believe produce year come health safety integrate ehs sustain high ehs performance need discussion system aim ensure issue risk combine structure ehs system external stakeholder identify standard establish adhere attitude value create positive ehs ehs issue say climate change energy conservation training provide target set audits culture achieve need embed eh pharmaceutical conduct awareness system gsk activity environment use hazardoustoxic chemical eh policy vision global ehs environmental sustainability believe key external challenge standardsset overall framework provide need embrace environmental sustainability work complete core site eh management toolkit driver competitive advantage programme ehs contain instruction description appropriate define principle management system achieve procedure help comply standard environmental sustainability progressively improvement target integrate business translate time stage background information approach practical action line advance qa continue manage environmental issue available knowledge environment health safetysection website gsk corporate responsibility report corporate responsibility report open transparent ehs external business sector develop objective step expand relation believe external support corporate target develop focus improve use stakeholder legitimate interest specific short mediumterm plan achieve natural resource step sustainability s company eh affair ready individual site set local target complex access relevant information contribute business target opportunity dialogue issue work material use annual action plan focus effort efficiency production concern believe build select priority issue theme energy open relationship partnership lead embed ehs business follow initial critical component business opportunity failure engage gsk adopt life cycle focus fundamental year damage reputation approach invest energy plan efficiency renewable energy aspiration support strategic theme ehs stewardship fact ceo objective performance target area request review mean care present thinking energy save measure progress target future decision build excellence use renewable energy ehs plan excellence initially set target time maintain high possible product stewardship area interim target standard business sector aspect sustainability encourage culture accept need focus issue report progress responsibility incorporate ehs pharmaceutical target environment planning business process plan year align highlight gsk business driver desire corporate ehs work business approval second stage plan excellence environmental sustainability determine element environmental introduce new target sustainability need focus begin stage plan promote environmental sustainability principle focus fundamental material efficiency target efficiency business improve performance simultaneously target resource consumption air area need emission water pollution waste disposal continue pilot programme develop second stage safety concern distribute product stewardship guide plan keen market product focus maintain ehs audit score measure improvement base success management system approach expand programme discussion ehs foundation new annual external stakeholder uk rest improvement target improvement target europe establish improvement company new target manufacture new baseline product stewardshipsection medicine background web page goal sustainability tangible standpoint annual reduction sale manufacturing function gms accept challenge energy board director iso stakeholder engagement ohsa certify solid waste embed management water stakeholder engagement play important role system business manage ehs section report create new ehs air emission volatile engagement specifically eh issue director position gms organic emission engagement stakeholder manage biological sit executive team help cr section detail engagement wastewater chemical eh integral business corporate responsibility issue oxygen demand decision addition inclusion dow jones qa continue material efficiency sustainability index uk ftsegood achieve average material efficiency glaxosmithkline rate business manufacturing process new product introduce environment bie premier league field participate company rating indicate extent interpret environmental cumulative target responsibility way manage business ozone depletion elimination environmental performance ehs audit score frequently engage ad hoc meeting range external stakeholder average help understand view identify minimum emerge issue step internal external engagement ehs issue long target area create formal stakeholder panel uk provide perspective ehs performance global warming potential replace panel facilitate environment council target energy efficiency independent charity member represent hazardous waste address customer supplier regulator public interest hazardous waste new material group investor plus senior ehs efficiency target representative gsk gsk corporate responsibility report corporate responsibility report plan system not provide opportunity ehs expert engagement ehs professional help gsk business meet stakeholder work detail programme energy need discuss emerge ehs issue feedback initiative great people develop ehs plan excellence right qualification training survey staff involve ehs working issue panel meet month assess success communication right culture discussion cover identify area improvement senior management complete internal review corporate support promote right engagement strategy behaviour investment environment health safety cehs take position need public position paper climate communication will not compromise changeenergy management management ehs framework document receive high environmental protection hazardous chemical pharmaceutical employee safetywe see mark usefulness source information environment final version approve consciousness environ ehs communitywebpage web gsk management publish ment health safety need userfriendly embed gskcom relaunch site business theme process safety incident irvine see find high awareness ehs site health safetysection reflect enhance attitude plan excellence ehs programmes chemical business eh strategic plan ehs agent process safety ehs reward move bolt control recognition programme theme exist process build ehs performance central sustainability people say need operation culture ehs align gsk business direction clear message especially priority change central second relationship overall mission stakeholder repeatedly highlight view stage year plan corporate ehs department gsk mean need important gsk address broad issue address address issue people climate change sustainable qualified train align development beginning address broader take feedback company wide plantsour infrastructure aspect sustainability example work gsk employee develop ehs properly design instal material efficiency strategic plan maintain process system management plan extend stakeholder engagement engagement regulator approach identifie risk activitie europe gsk keen proper measure place develop programme year begin protect environment safeguard manage risk stakeholder engagementbackground page development launch new medicine priority time regulation need workable theme ehs local engagement industry avoid unnecessary cost bureaucracy stewardship mean site engage stakeholder want embe locally activity open day collaborate regulator help new culture business develop effective control newsletter community project example people understand dresden site conduct intensive engaged regulator uk shortterm exercise need communication local community ahead government work improve regulation vision understanding doubling manufacturing capacity flu business submit comment ehs longterm impact vaccine construction activity particularly regulation consider review sensitive site residential area practicability host visit well need think work place ceo ehs excellence regulation commission pilot plant environmental impact award community project demonstrate issue climate change embe inherent safety participate house commons select conduct survey ehs stakeholder life cycle product committee inquiry work engagement gsk site world raw material waste environment agency change reflect find site engage frequently gsk manage ehs eh local government emergency service work trade association include benefit gsk example neighboursresident association local environ british european pharmaceutical industry address climate change mental advocacy group local business ehs group improve energy partner site report open dialogue efficiency benefit engage consultation process community helps build strong relationship environment european union regulation registration financial benefit gsk dispel preconception particular report evaluation authorisation chemical reach beneficial involve local community qa continue globally harmonise system ghs environmental risk assessment develop classification labelling chemical gsk ment emergency response plan site waste support aim initiative protect management plan human health environment please internal engagement outcome effort engage gsk staff party achieve workable regulation continue business way include discussion play development support business leader debate agree way guidance reach forward ehs gsk especially agree annual action plan position paper specific issue energy gsk corporate responsibility report corporate responsibility report welcome introduction formal guideline awareness gsk planning conduct environmental risk assessment raise profile environmental issue basic environmental establish eus new medicine variety mean include ehs framework protection address sustainability broadly legislation gsk lobby environmental plan excellence chief executive mention impact pharmaceutical regulate solely officer eh excellence awardsscheme step sustainability european agency evaluation bar page place concern efficiency medical product winner use material propose reach framework lead energy manufacturing duplication effort place unnecessary run earthweek june coincide process new world environment day send target double efficiency burden pharmaceutical industry information kit site help develop manufacture new detail public policy manage idea plan activity site product introduce date hope cr section country celebrate earthweek activity start use raw involve employee material renewable example activity resource petrochemical gsk site mississauga canada celebrate distant future training awareness earthweek planting seedling small want biological transformation raise employee awareness environment tree indigenous local area chemical synthesis health safety issue improve skill involve employee needs happen inherent training key part ehs gsk employee civac consumer safety build programme critical embed healthcare site mexico raise framework building eh culture environmental awareness group local business employee level need school child show understand ehs issue work separate household waste recycling environment example employee need understand property hazard necessary cover ehs issue regularly eh bulletins precaution associate chemical article gsk internal magazine gsk spirit handle handle waste need know espirit encourage employee consider property regulation govern disposal environmental issue outside workplace material recycle minimise household waste save energy water help employee deal issue meeting bulletin information intranet information ehs communicationon site specific training event background page eh standard training intranet site myehs community contain link range programme include ehs managerinformation system contain policy standard guideline tool training material example good practice news provide customise management report ehs performance site training training take place site level programme routinely include induction train new employee eh training accessible mylearning gsk online training service carry additional ehs manage ment training consumer healthcare regional pharma supply organisation site visit oneonone training use ehs managersoftware system ehs manager encourage attend conference training programme sponsor local environmental organisation academic institution gsk corporate responsibility report corporate responsibility report barnard castle uk ehs excellence awards site huge progress reduce environmental ceo ehs excellence awards recognise weakness identify audit auditor impact year reward gsk site leadership ehs monitor site progress implement plan cut electricity use programme expand include internal auditor certify lead auditor percent gas percent aspect sustainability award recognise international environment health water consumption percent people exceptional work safety management standard iso promote implement ehs project ohsa site expect conduct site energy audits highlight innovation example good practice routine self audits ehs programme identify potential saving improvement heating ehs management share site majority audit conduct cool equipment winner receive trophy select charity new riskbase process focus significant installing automatic light receive donation gsk operational ehs risk environmental impact controller optimise boiler control winner excellence awards range applicable ehs demonstrate project standard audit frequency determine poster special event improve environmental performance save consider key site risk demonstrate encourage employee play employee energy money performance manage effectively warden fifth year award conduct corporate audits site assign department help limit energy use entry country include office location average score area warden train application gsk business sector rd percent compare percent identify potential energy manufacture commercial facility site achieve score percent saving sure equipment management team regard unacceptable aim correct efficiently unacceptable performance continue pursue raise awareness winner choose panel include improvement achieve good practice colleague expert academia government public site instal interest group project represent good level performance find kw wind turbine reduce europe north america central america site especially area cover gsk energy middle east asia receive honours environmental standard aspect fossil fuel source earn identify improvement especially safety issue site regional award place award winner health safetypage act example feature page detail local industrial complex ceos ehs excellence award background site achieve leadership score instal page percent similar turbine achieve score percent seven barnard castle energy initiative reduce good performance environmental issue coemission total tonne save audits compliance million management solid waste project place request audit committee board air emission ehs initiative environment director gsk embark programme category achieve iso ohsa emergency planning poznan poland certification site generally weak poznan site found gsk science public centre leadership gsk manufacture self auditing inspection division gms approve fouryear programme centre meet venue community certify remain gms site iso ohsa risk assessment process education event public programme begin early biodiversity healthcare disease complete site prevention community achieve certification additional compliance education run gsk site certify iso ohsa minimum policy comply legal employee organise bring total dual certify site requirement fine penalty activity include mean pharmaceutical report regret help teacher promote consumer manufacturing site certify breach regulation case prompt healthy behaviour site certify iso federal aviation administration issue student warn letter penalty non workshop teaching carry regular ehs audits gsk compliance shipping regulation deficiency pupil operation contract manufacturer key poznan high school supplier aim assess control deal threat risk comply key legislation extent noncompliance mark label drug hivaid management system standard documentation shipment inhalation aggressive behaviour implement improve performance aerosol alcohol maintain compliance supply chainpage inoperative emergency number hazard help people disability information include human right information audits theatre performance undeclare dangerous good flammable local community audit programme require manufacture liquid ship interoffice mail project place rd site undergo ehs audits internal ehs community partnership audit team audits occur year category depend assessment risk site require develop plan address gsk corporate responsibility report corporate responsibility report material efficiency aim improve efficiency vastly reduce use solvent convert raw material finish product waste percent reduction mass drive environmental sustainability help waste avoid tonne waste reduce consumption resource annum waste generate cost production robust previous process set target double average material result waste fail batch efficiency manufacturing process new reduce exposure employee hazardous product introduce material achieve material efficiency percent new process ie tonne active chart show extent pharmaceutical ingredient api improve material efficiency compound tonne input chemical development stage datum relate compound development pharmaceutical process typically complex require large amount solvent typically industry use tonne material tonne api produce percent mass productivity distribution material efficiency compare percent fine chemical percent bulk chemical represent waste valuable resource financial environmental consequence approach address ehs issue include minimise material example ecodesign toolkit place high priority improve use material bring rd manufacturing team increase material efficiency product development stage select exist product key measure material efficiency mass productivity mass material water include solvent process compare mass product produce new percent target apply measure early development compound make improvement material mass productivity percent efficiency example research development proportion low level efficiency fall team stevenage uk rd site work stage stage development cork ireland site achieve substantial transfer manufacturing majority achieve environmental benefit develop simplify productivity percent process manufacture dutasteride treatment percent process achieve benign prostate hyperplasia project productivity percent continue deliver benefit work place green chemistry category chief executive officer eh excellence awards new process produce percent drug substance start material save millionyear save energy chemical reaction require hour c compare hour c previously gsk corporate responsibility report tnecrep stevenage uk rd site stevenage reduce environmental impact manufacture compound development stage original process manufacturing drug involve use seven different solvent number hazardous chemical produce low yield high waste volume team stevenage develop new technique triple material efficiency percent percent reduce waste percent organic solvent hazardous chemical require energy majority waste handle site project place green chemistrytechnology category stage stage stage stage mass productivity mass productivity mass productivity mass productivity corporate responsibility report product stewardship address environmental issue associate module design ensure ehs product life cycle begin impact material process service product design continue consider manufacture raw manufacturing eventual disposal refer material ultimate fate product product stewardship waste environment section cover product design include toolkit approach packaging impact pharmaceutical product designin background page environment research development section report cover approach animal testingread environmental issue associate product package background page work improve environmental product design performance packaging area environment health safety staff work product development team incorporate ehs green packaging guide provide guidance consideration design product business process evaluate select source material identify residual ehs risk packaging option include interactive product rd manufacturing wizard know wrap wizard rapid assessment packaging help package ecodesign toolkit designer manager benchmark new develop ecodesign toolkit exist packaging design consider metric scientist engineer use identify process product life cycle improvement address ehs issue early development process toolkit available manufacture material gsk intranet consist module mass material green chemistrytechnology guide biodegradability help gsk scientist engineer apply green chemistry concept achieve efficient pvc content use resource reduce ehs impact resource depletion minimise cost example bottle consumer product material guide contain information lucozade illustrate range work range material gsk packaging operation include solvent avoid guide cover solvent selection reduce packaging move second deal chemical base glass plastic bottle make huge selection save weight energy transport cost progressively reduce weight green packaging guide assessment plastic bottle percent tool include guidance business process evaluate select packaging increase use recycle material bottle option packaging currently contain percent recycle material intend increase flascfast lifecycle assessment synthetic percent soon develop chemistry webbase tool process reliable supply allow bench chemist perform streamlined life cycle evaluation environmental improve design facilitate recycling impact new exist process base bottle recycle easy clear bottle material flaschelps scientist contaminate residue manager rapidly identify greenest change coloured clear bottle material option compare develop shrink sleeve benchmarking process identifie need adhesive easily separate material significant life cycle promote recycle community environmental impact provide guidance active member recoup charitable reduce impact organisation promote plastic recycling chemical legislation guide clg uk wwwrecouporg recoup gsk identify legislation part world key contributor study design aim phase hazardous substance recycle plastic container routine use clg provide riskbase fund project promote recycle guidance variety chemical plastic container provide reverse concern easily accessible form vend machine public place gsk corporate responsibility report corporate responsibility report investigate biodegradable plastic engage joint project pharma follow development material ceutical industry pharmaceutical polylactic acid pla corn starch research manufacturers america phrma currently believe return recycle conventional pet bottle good gsk model upgrade environmental option pharmaceutical assessment transport packaging type aim use evaluation phatetm model good type container product estimate potential environmental impact example use carton tetra paktmfor sewage sludge apply land phate ribena minimise weight improve risk assessment base specific distribution efficiency recycle local stream flow population pattern system development contribute develop database packaging impact invest scientific literature impact distribution centre close bottle pharmaceutical aquatic life supply company mean contribute analysis impact maximise efficiency lorry movement unused medicine environment report share regulatory agency develop paper publication scientific literature pharmaceutical continue work area environment medicine work active pharmaceutical conduct chronic ecotoxicity testing ingredient apis absorb patient select apis base new eu guideline body material include use guideline integral absorb eventually excrete environmental risk assessment strategy bodys normal mechanism enter sewage continue comprehensive environmental risk system wastewater treatment plant remove assessment apis develop pharmaceutical residue small concentration allowable daily intake level human end river sea area consumption drinking water fish wastewater treatment high concentration enter consumption noeffect level environment aquatic organism quantitative risk gsk develop business process ensure assessment compare level carry appropriate environmental test predict environmental concentration environmental risk assessment present datum select set approval process new medicine eu compound scientific meeting provide regulatory agency provide datum risk assessment assessment evaluate allow mitigation gsk apis swedish association potential environmental impact pharmaceutical industry lif industry group meet voluntary programme provide datum regulatory agency issue include food physician gsk technical drug administration environmental team develop lif guide document protection agency environment guidance pharmaceutical company agency england wale risk assessment indicate product appear pose appreciable risk human approach pharmaceutical environment base current method environmenton background page ascertain safe level continue monitor late scientific study finding improve risk assessment area work pharmaceutical company university research group develop science methodology assess environmental risk pharmaceutical environment increase understand risk start investigate issue mixture pharmaceutical establish relationship brunel university uk develop research plan addition house programme gsk corporate responsibility report corporate responsibility report environmental performance continue improve use energy reduce emission atmosphere slightly water generate waste succeed keep percentage increase percentage rise sale scope datum manufacture pharmaceutical energy efficiency environmental datum cover consumer product process calendar year need energy discover develop manufacture involve chemical need collect distribute medicine energy use pharmaceutical consumer understand address report environmental facility especially manufacture manufacture site impact include issue common rd office site global manufacturing biological site manufacturer use energy water operation pharma waste handle common supply gms research development ceutical consumer research rd account percent percent sector need consider potential impact development site respectively consumption certain chemical release volatile major office location concentrate effort increase include available data site organic compound vocs manufacture energy efficiency transport main source operation asthma inhaler mean use chemical remain energy use year damage ozone layer require environmental datum improve energy efficiency help reduce small office distribution review reporting consider global warming impact widely accept centre materiality environmental impact light activity human change planet pharmaceutical industry practice global note attach data table climate scientific consensus explain scope reporting initiative input greenhouse gas ghgs carbon dioxide datum collection process stakeholder methane cause greenhouse effect parameter detail specify unit stakeholder tell want simplicity trap heat earth atmosphere sale figure absolute reporting need appropriate level cause global increase temperature burn number ie total consumption detail try balance fossil fuel greatly increase presence energy water etc conflict requirement example gas atmosphere expert reduce simplified graph agree increase ghgs cause earth chart report concentrate area warm process bring target include data table disastrous change climate completeness environment continue work minimise energy use section emission despite expect growth new concentrate report product require additional energy expect continue find opportunity great issue potential financial benefit impact efficiency new exist facility gsk material efficiency energy operation result new target reduce efficiency energy consumption percent unit sale issue directly relate use chemical year volatile organic compound chemical finalise position paperon future oxygen demand wastewater hazardous use energy follow extensive internal waste external consultation position paper set seventh year report strategy energy efficiency renewable energy gsk environmental performance legacy emission trading commit gsk company report year reduce reliance fossil fuel creation gsk copy report technically economically possible available corporate register support effective marketbase mechanism verification emission trading seek reduce data environment section emission health safety page employment section report externally verify sgs uk ltd evaluate use renewable energy detail find verification statement evaluate energy investment lifetime normal payback period gsk encourage supplier contractor employee improve energy consumption report transparently energy consumption internationally recognise protocol gsk corporate responsibility report corporate responsibility report energy performance energy consumption million gigajoule energy approx imately percent buy percent energy electricity generate rest target fossil fuel burn site reduction energy use come despite increase sale energy consumption sale percent low baseline continue work energy efficiency initiative active energy team manufact ure rd energy manager large site example include instal energy efficient lighting motion sensor thermographic survey identify heat loss result insulation repair baseline ultrasonic survey identify air leak site voltage reduction project efficiency improvement heating ventilation air gigajoule million sale conditioning target retrofitting economiser steam boiler steam trap survey energy consumption maintenance improvement year gjper million sale electricity steam metering improvement centralise monitoring target software system refrigeration chiller efficiency improvement datum table include additional detail energy greenhouse gas emission amount renewable energy electricity purchase fuel start invest renewable energy instal combustion capacity require consume carbon dioxide project example barnard castle instal participate gsk site cover equivalent emission wind turbine site solar balance gsk surplus carbon credit energy source inhaler production use energy heat water site purchase proceed sale carbon credit invest electricity renewable resource energy efficiency project future report electricity energy investment renewable source adopt approach energy emission trading investment reflect longterm nature number uk site participate project importance energy supply government emission trading scheme ets business instead apply normal help gain experience carbon trading investment criterion assess return uk ets voluntary scheme reward investment project lifetime company low energy taxis improve expect result approve energy energy efficiency site emission efficiency renewable energy project agree target bank spare credit help qualify normal investment comply limit subsequent year criterion sell credit participant scheme project approve solar water gsk site comply climate heating site slough uk change agreement european union trading scheme come force start initial threeyear period site megawatt gsk corporate responsibility report corporate responsibility report transport estimate transport account million launch number initiative reduce kilogram co percent global impact transport product include warm impact energy consolidate freight shipment pharmaceutical consumer product transport business air travel account half consolidate shipping point make use percent travelrelate coemission round trip manage inbound freight truck employee travel total return switch million kilometre plane result air sea transport possible million kg coemission air travel include group travel originate outside uk green travel plan number site global sale fleet drive total billion encourage employee reduce environmental kilometre business travel result impact travel work example gsk million kg co house brentford uk privilege parking space give carsharer driver fuel efficient addition business travel transport car bus power biodiesel run product manufacturing plant local train station change room distributor gsk product shower provide cyclist discount transport total million kilometre bicycle equipment repair begin majority percent air freight estimate use hybridengine car chauffeur service air freight result million kg cowhile ocean road freight result additional encourage employee use video million kg co teleconference possible reduce air travel virtual meeting software available employee year greenhouse gas protocol make presentation collaborative working calculation coemission gsk employee conduct able obtain detail freight video meeting teleconference shipment detail web conference precise calculation coemission freight transport change unable compare coemission transport previous year work obtain level detail passenger air travel gsk corporate responsibility report corporate responsibility report water performance water consumption million cubic metre water percent spite small increase water consumption rise sale water consumption target sale percent low consumption average industry base benchmarke major pharmaceutical company baseline water usage go mainly increase activity biological site especially high vaccine production biological belgium high production manufacturing plant ireland uk require water increase partly offset partial closing site small improvement site result water conservation measure baseline cubic metre million sale target water consumption year million sale water use gsk use water manufacturing process product cool clean general site use include drink food service sanitation primary supply site manufacture active pharmaceutical ingredient typically heavy user water site manufacture vaccine produce drink involve research development commercial activity typically use water valuable natural resource need conserve especially area shortage protect pollution gsk water standard require site minimise water use reuse water feasible ensure wastewater treat discharge way minimise adverse environmental impact target reduce water consumption percent annum sale gsk corporate responsibility report corporate responsibility report wastewater performance chemical oxygen demand wastewater generate million cubic metre wastewater total volume percent reduction partly change site include target new specialised wastewater treatment facility primary manufacturing plant remove solvent wastewater closure manufacturing operation baseline plant change wastewater treatment product mix total chemical oxygen demand cod discharge onsite treatment million kilogram percent reduction cod sale percent baseline kilogram million sale target chemical oxygen demand wastewater year kgper million sale wastewater site discharge wastewater municipal domestic activity washrooms treatment facility large site especially canteen vast majority cod come primary manufacturing onsite manufacturing contribution wastewater treatment system site activity sufficiently significant permit discharge wastewater direct sea warrant time effort require collect datum change result decrease assess quality wastewater measuring report cod percent chemical oxygen demand cod oxygen recalculate prior year datum require chemically oxidise compound comparable water low cod clean water target improve cod discharge percent year sale change cod measurement concentrate wastewater manufacturing process exclude site waste mainly gsk corporate responsibility report corporate responsibility report waste research production commercial activity nonhazardous waste produce waste aim manage safely nonhazardous waste general material responsibly generate final office waste paper kitchen waste non disposal want eliminate waste hazardous substance manufacturing reduce reuse material small biological waste possible recycle waste dispose treat hazardous include remain material sensitively construction demolition rubble similar material relate daytoday operation generate different kind waste different describe separately nonroutine waste part business continue look way reduce waste production hazardous waste solvent undertake waste management review chemical site new target reduce non rd quality laboratory small amount hazardous waste sale percent chemical include product annum intermediate break glassware hazardous waste plastic percent hazardous waste office paper standard commercial consist solvent production waste process dispose lubricant fluorescent light research waste include renovation place production office animal carcass lab space produce nonroutine waste obsolete equipment office furniture regulation vary widely world structural material choice solvent reuse recycle material possible main disposal active ingredient pharmaceutical option solvent incineration aim recover product manufacture chemical energy incineration possible process mean significant proportion waste classify hazardous hazardous waste dispose contain solvent chemical process classify waste hazardous non hazardous nonroutine waste construction demolition rubble baseline production facility segregate waste reuse send recycle incinerate landfill incineration usually prefer choice deal solvent not reuse recycled practicable site use waste management company use incinerator recover energy burn material require disposal contractor comply baseline ehs requirement local regulation site audit waste contractor hire consultant carry audits kilogram million sale continue work reduce waste especially target hazardous waste improve material efficiency reduce waste especially number volume hazardous waste dispose solvent set target increase material year kgper million sale efficiency new product go rd manufacturing percent past waste chemical handling practice contaminate landand groundwater practice long follow hazardous waste come primary continue clean site deal production activity concentrate health environmental hazard effort stop collect hazardous waste datum consumer manufacturing plant gsk heritage company spend laboratory office secondary manufac cleaning site ture site site produce percent year continue clean hazardous waste past site waste disposal site gsk set target reduction hazardous responsible party figure include waste target improve material efficiency datum verification gear accomplish reduction hazardous waste gsk corporate responsibility report corporate responsibility report waste performance nonhazardous waste dispose generate million kilogram hazardous waste million kilogram nonhazardous waste recycle million target kilogram waste million kilogram hazardous million kilogram non hazardous represent percent total generate exclude non baseline routine waste proportion waste recycle percent lower dispose landfill incineration million kilogram hazardous waste million kilogram nonhazardous waste total hazardous waste dispose percent higher adjust rise sale percent low baseline hazardous waste solvent percent rest general site waste incinerate percent hazardous waste dispose energy recover percent kilogram million sale target total nonhazardous waste percent low dispose sale decrease percent nonhazardous waste dispose year non hazardous waste generate year kgper million sale send percent landfill recycle recycle hazardous nonhazardous waste site india stop land fill coal aiming minimise environmental impact ash generate site instead sell raw cost material waste material production construction material large waste component solvent addition nutritionaldrink manufacturing manufacturing process site send process waste barley husk solvent purify site reuse animal food recycle canteen waste original manufacturing process sell effluent treatment plant sludge convert solvent commercial reprocess company biocompost include recycle statistic datum table include additional solvent recycle way usually detail waste amount hazardous incinerate nonhazardous waste recycling recycle nonhazardous waste paper landfill incineration non cardboard glass plastic aluminium usually routine waste mean send reprocess reuse new product gsk corporate responsibility report corporate responsibility report ozone depletion performance ozone depletion potential total ozone depletion potential odp production inhaler equipment thousand kilogram percent lower base estimate target emission equipment ozone depletion potential estimate equipment production loss sale percent low baseline cfc cfc contain piece equipment amount kilogram cfc thousand item equipment contain ozone deplete substance odp kilogram cfc equivalent estimate percent kilogram cfc equivalent release equipment estimation factor british baseline refrigeration association kilogram million sale target ozone depletion potential year kgper million sale ozone depletion ozone layer essential human survival chart refer od lose production filter harmful ultraviolet uv ray activity equipment leakage data table sun damage ozone information patient use deplete substance odss mainly chlorofluoro inhaler carbon cfc hydrochlorofluorocarbon hcfc instal new equipment help halon meet target eliminate cfcs main use odss past equipment productuse apart propellant gas meter dose inhaler mdi halon fix fire protection system equipment asthma sufferer gas release patient contain kilogram cfc use inhaler small escape thousand kilogram cfc propellant production past cfc release patient product switch hydrofluorocarbon hfcs dry small thousand kilogram powder technology require release production inhaler propellant hfc deplete ozone layer estimate kilogram cfc equivalent contribute global warming emit equipment use odss cool system ancillary use gsk facility switch hfcs ammonia hydrocarbon ammonia contribute ozone depletion global warming hydrocarbon small global warming impact gsk corporate responsibility report corporate responsibility report equipment production meter dose inhaler odss mainly hcfc seal inside cool meter dose inhalersmdi commonly system release event leak deliver main form treatment asthma maintenance sufferer pressurise handheld device use propellant deliver dose medication way eliminate emission eliminate patient lung introduce cfc hcfc cool system cfc traditionally new strategy propellant nontoxic nonreactive carry inventory cfc nonflammable odour hcfc contain equipment repeat taste exercise quarter annually patient use mdi propellant monitor decrease cfc content release atmosphere montreal collect datum hfc protocol ban production cfc exempt recognise risk catastrophic number essential use include mdis failure equipment large release plan eliminate use cfc eliminate chemical focus worldwide product portfolio attention large piece equipment stop cfc remove service end european union offer selection intend replace equipment contain alternative odscontaine inhaler kilogram typically countrie main alternative propellant use hermetically seal likely leak hfc affect ozone long collect data loss equipment high global warming potential concentrate eliminate cfc invest heavily dry equipment control release powder delivery system use cfc comparison prior year estimate hfcs percent total cfc hcfc continue manufacture cfc mdi india lose remain equipment odp china pakistan use subcontractor chart show emission produce inhaler produce cfc devices bangladesh latin estimate emission equipment america market target year report kg release base loss eliminate cfc equipment failure replacement ozone depletion potential patient use meter dose inhaler percent lower previous year information eu data india pakistan china calculate decrease cfc inhaler produce production cfccontaine mdi decrease cfc lose production decline total ozone depletion potential production percent low gsk corporate responsibility report corporate responsibility report control volatile organic volatile organic compound emission compound emission gsk cork site voc arise process cork use solvent dichloro methane ethyl acetate target ethanol introduction uk air pollution act lead focus control elimination solvent emission carry complete review baseline point emission solvent emission reaction vacuum pump discharge centrifuge pressure filter tank collect sitewide system pass high temper ature incinerator operate c destroy organic vapour efficiency great percent emission incinerator baseline stack continuously monitor voc residue carbon monoxide sulphur oxide nitrogen oxides hydrogen halides incineration operation kilogram million sale regard well available target technology efficient destruction voc prevention emission substance atmosphere volatile organic compound emission control voc ulverston year kgper million sale manufacture intermediate stage antibiotic cefuroxime axetil use solvent include dichloromethane dcm tetrahydrofuran thf gsk approve project install carbon adsorption unit remove vocs process stage carbon adsorption technology volatile organic select methodology compound reduce voc emission technology offer robust use volatile organic compound voc mainly target reduce vocs industry standard abatement solvent primary manufacturing operation percent annum sale improvement solution represent good rd pilot plant solvent coat voc emission available technology tablet clean sterile operation project primary manufacturing site capture exist vent air use small quantity laboratory fugitive emission change production redirect carbon measure emission use change way voc emission calculate adsorption unit adsorb activate alignment local regulation voc react nitrogen oxides presence carbon bed system operate sunlight create ozone low atmosphere photochemical ozone creation potential continuously use steam regeneration remove result smog factor human percent low adsorb solvent respiratory illness workplace exposure certain change way measure voc recover site voc pose health risk exclude small quantity laboratory exist solvent recovery unit reuse process release million kilogram voc estimate percent total voc emission atmosphere percent low prior year recalculate voc emission project remove emission sale percent prior year comparable tonne annum dcm release air low tonne annum thf site save estimate k annum recovery reuse solvent gsk corporate responsibility report corporate responsibility report independant verficationassurance statement wwwsgsukltd sgs united kingdom ltds report environment health safety data glaxosmithkline environment health safety ehs report nature scope verificationassurance sgs united kingdom ltd commission glaxosmithkline conduct independent assurance ehs report scope assurance base sgs sustainability report assurance methodology include environment health safety performance data graph contain page report accompany table page datum relate contaminate land page health safety datum relate nongsk employee include assurance process financial datum draw directly independently audit financial account check source assurance process information ehs report glaxosmithkline presentation responsibility director management glaxosmithkline sgs united kingdom ltd involve preparation material include ehs report responsibility express opinion datum graph relevant statement scope verification sgs group develop set protocol assurance sustainability report base current good practice guidance provide global reporting initiative sustainability report guideline aa assurance standard datum report assure protocol content veracity assurance comprise combination interview relevant employee evaluation datum collection submission methodology documentation record review validation external body andor stakeholder relevant site visit uk usa belgium italy singapore site contact telephone uk usa ireland india australia site select include submit high proportion key datum include part gsk business additionally visit corporate head quarter webconference key individual utilise order complete verification activity statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence glaxosmithkline free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor register irca iema emas verifier verificationassurance opinion basis methodology describe verification work perform satisfied datum contain glaxosmithkline ehs report reliable provide fair balanced representation glaxosmithkline ehs activity believe glaxosmithkline choose appropriate level assurance stage report gsk corporate responsibility report corporate responsibility report independant verficationassurance statement key area improvement datum collection submission manipulation identify follow definition datum submit fully understand adhere consistently site level estimation calculate certain datum guidance provide site ensure calculation approach consistently establish rigorous process check enter datum anomaly datum enter error miss datum consider incorporation internal audit datum datum management system alongside corporate ehs audits ensure training undertake key individual replace ensure consistency understanding system requirement ensure site submit datum comment include explain estimation calculation significant change ensure process extract datum electronic system consistently appropriately enable correct value obtain individual utilise system key area improvement datum verification process identify follow ensure relevant datum available internally check advance external verification process behalf sgs united kingdom ltd pauline earl business manager systems services certification february gsk corporate responsibility report corporate responsibility report global warming potential global warming potential metric gwp energy source calculate co coequivalent energy use greenhouse gas ghg energy operation protocol develop million gigajoule world resources institute world business natural gas council sustainable fuel development coal gwp air land steam import sea transport calculate ghg protocol electricity import distance travel directly fuel global warming potential coequivalent year gwp operation collect energymillion kilogram category freight natural gas transport employee business travel fuel miss coal group air travel originate outside uk steam import motor vehicle travel electricity import conversion assume medium vehicle sale employee heavy gwp transportmillion kilogram diesel vehicle freight sale force transport air travel gwp refrigerant product logistic release equipment calculate factor kyoto protocol gwp production change activity million kilogram collect data release refrigerant inhaler production loss collect data equipment contain great refrigerant kg refrigerant contain equipment calculate comethane nitrous oxide release factor waste treatment british refrigeration source association probable leakage calculate release gwp use inhaler refrigeration equipment patientsmillion kilogram hold great kilogram refrigerant cfc inhaler gwp ozone cfc inhaler deplete substance hfc inhaler inhaler use factor kyoto protocol water use discharge information calculate water million cubic metre gwp inhaler use previous year municipal well borehole water water source water include recycle source wastewater volume million cubic metre ww recycling ww municipal sewer ww water body cod onsite treatment million kilogram cod recycle water cod sewer cod water body gsk corporate responsibility report corporate responsibility report wastewater metric change wastewater calculation include wastewater volatile organic compound emission chemical oxygen demand major volatile organic compound emission contributor primary million kilogram operation pilot plant pocp total voc emission coat sterile operation recalculate datum previous year solvent release million kilogram compare acetone chemical oxygen demand cod measure water dichloromethane pollution manufact methanol ure process measure wastewater leave ethanol site follow isopropanol site treatment volatile organic compound change ozone deplete substance calculation include od release voc major production thousand kilogram contributor primary operation pilot plant cfc release production coating sterile operations recalcul cfc release production ate datum previous year compare od release addition kilogram equipment thousand kilogram voc emit calculate photochemical ozone cfc release equipment creation potential pocp cfc release equipment kilogram ethylene equivalent conversion od ancillary equipment ethylene equivalent base european chemical industry council od release patient use cefic responsible care inhalersthousand kilogram hse report guideline cfc patient use voc cfc patient use ozone deplete substance ozone depletion potential odp ozone deplete od contain substance calculate factor kyoto equipmentthousand kilograms protocol previous year waste generate disposed information inhaler produce asia hazardous waste generate emission patient use million kilogram previous year hazardous waste recycle information hazardous waste dispose od contain equipment hazardous waste incinerate waste energy recovery consider waste hazardous waste incinerate hazardous radioactive energy recovery bioengineere biohazardous hazardous waste landfill property define basel convention include flammability nonhazardous waste generate explosivity water air million kilogram reactivity corrosivity oxidise potential acute nonhazardous waste recycle chronic toxicity ecotoxicity nonhazardous waste dispose infection biological waste render non nonhazardous waste incinerate hazardous treatment energy recovery consider nonhazardous nonhazardous waste incinerate waste energy recovery nonhazardous waste landfill gsk corporate responsibility report corporate responsibility report change calculation include metric hazardous waste major contributor primary nonroutine waste generate operation pilot plant coat sterile million kilogram operation nonroutine waste recycle recalculated data nonroutine waste dispose previous year compare nonroutine waste incinerate incineration energy energy recovery recovery mean burn nonroutine waste incinerate material energy recovery result energy nonroutine waste landfill nonroutine waste include construction demolition rubble estimate cost investment include hazardous operation maintenance nonhazardous waste calculation cost million injury illness capital investment million health safety datum cover employee injury illness gsk employee contract worker directly supervise hour work million gsk employee report fatality snapshot injury number injury lose time illness performance year case calendar day lose injury add late number illness lose time correct prior year calendar day lose illness lose time injury number injury lose time illness workrelate injury illnesse number illness lose time result day injury illness non gsk employee verify sgs away work hour work million lose calendar day fatality calendar day employee work number injury illness workrelate lose time injury illnesse calendar day lose include weekend helps provide measure number injury illnesse severity injury lose time illnesse reportable injury illnesse lose time report incident result time away work lose time aid generally lose time gsk corporate responsibility report corporate responsibility report work community donation money medicine time equipment support underserved community world focus investment programme relevant business skill people improve healthcare education detail criterion give support available gskcom believe profit total community investment include award benefit underserved community million million cash grant receive responsible company million million management cost world business award support business international gsk member uks percent club chamber commerce demonstrate commitment tackle company donate percent united nations healthcare education challenge pretax profit charitable cause gsk development programme list sixth uks guardian give list prince wale make employee feel proud work list ftse company percentage international business leader gsk forum lymphatic pretax profit contribute charitable cause filariasis elimination improve reputation stakeholder fifth year row programme big overall giver value donation community investment link short term excellence corporate business benefit intend create belong uks london benchmarking philanthropy award commercial market gsk group lbg committee encourage base committee corporate philanthropy cecp report encourage corporate donation group level support philanthropy cecp donation line cecp guideline disease prevention increase healthcare capacity value medicine wholesale acquisition cost frost sullivan develop country individual gsk site pharmaceutical company wholesale global excellence award support local community malaria prevention acquisition cost wholesale list price treatment total community investment include discount star business value million million equivalent commitment education percent pretax profit method give million award philadelphia education fund objective ensure project management cash sustainable long term continue cost global health award funding come end leadership scientific inkind excellence new york community investment nonprofit academy science organisation expert field healthcare education help ensure platinum ounce award russian pharma giving target effectively community ceutical industry gsk need russia leadership multi colour life project value community investment product gsk donation value million breakdown cash give million compare million million equivalent percent environment pretax profit compare percent art introduction new medicare prescription culture health drug benefit mean few patient request help patient assistance program result donate medicine worth million million lowincome patient compare million million addition million million humanitarian product donation underserve community world donate albendazole tablet value million million lymphatic filariasis elimination education programme gsk corporate responsibility report corporate responsibility report investment global public health initiative great contribution donate million albendazole healthcare develop country treatment million worth million research new treatment vaccine million value wholesale price preferential pricing make lifesave medicine country donate million affordable treatment new country join programme help address barrier access medicine investment give million million community health programme grant support global alliance eliminate lf donate money medicine expertise country start integrate lf support initiative improve healthcare raise programme neglect tropical disease awareness disease prevention develop prevention initiative extend benefit country public health zanzibar example take integrate approach distribute treatment focus major programme parasitic disease schistosomiasis develop world bilharzia onchocerciasis river blindness found member global alongside lf treatments alliance eliminate lymphatic filariasis lf country aim eliminate lf treat elephantiasis risk people drug albendazole positive action programme reduce diethylcarbamazine mectizan year stigma improve capacity hiv aid year far egypt pacific island prevention treatment country sri lanka zanzibar togo complete annual mass drug administration african malaria partnership support mobilise malaria advocacy initiative country monitor population generate political commitment funding evaluate impact programme combat malaria addition behaviour disease bill melinda gates change initiative foundation donate million operational research help evaluation phase education programme prevent assessment conduct egypt show lf diarrhoearelate disease hand eliminate area country washing gsk global alliance received donate essential antibiotic world business award international product response humanitarian disaster chamber commerce lf programme support basic healthcare provision impoverished community mectizan register trademark merck co initiative deliver partnership future challenge nonprofit organisation subsaharan africa present significant challenge follow progress country commence lf elimination programme lack funding eliminate lymphatic filariasis lf health infrastructure country donate medicine albendazole start lf programme need additional resource global programme eliminate lf enable scale reach atrisk wwwfilariasisorg lf disfigure disease population additional challenge prevalent tropical country transmit integration lf programme intervention mosquito lead severe swelling neglect tropical disease involve arm leg breast genital thicken coadministration albendazole skin lf world lead cause medicine permanent disability billion people country percent positive action hiv aid world population risk infection positive action programme set support community affect hiv global programme lead world health aid aim strengthen capacity organization government community organisation provide hiv aids endemic country aim eliminate lf prevention education healthcare services key treat billion people risk area focus reduce stigma discrimination commit donate free charge dose major barrier control hiv aids albendazole antiparasitic drug increase number people come forward prevent transmission lf need testing treatment recognise involve expect require billion tablet team people affect hiv aids key control gsk employee help global alliance hiv pandemic advocacy research community mobilisation education initiative support positive action programme run country gsk corporate responsibility report corporate responsibility report activity include scale national hiv prevention effort asia operate country high hiv prevalence asia tipping point research suggest ukraine russia china india kenya nigeria catastrophic hiv aids epidemic botswana rwanda belize jamaica region disease prevention treatment effort information preferential pricing improve access hiv therapie arrangement hiv aids medicine knowledge use correctly critical effective treatment partnership american foundation aids research gsk african malaria partnership amfar positive action support treat asia african malaria partnership support network clinic hospital research institution education behaviour change initiative patient support organisation help african country partnership ngos community prepare new treatment freedom hunger african medical programme launch region research foundation amref plan include community project china cambodia international invest thailand vietnam creation regional million million target approximately advocacy network million people foster effective prevention prompt treatment particularly india surpass south africa country young child pregnant woman hiv infection world positive action vulnerable malaria funding support freedom hunger reach india initiative come end project aim tackle cultural social support longterm positive impact factor expose woman rural india hiv target community reach india self help group establish respected mean woman access scale malaria problem require information support educate woman significantly big response give hiv aid reach woman million million grant year million family member year support mobilise malaria advocacy train local organisation deliver education initiative generate great awareness political project commitment sustain funding combat disease national coalition malaria mexico launch uk belgium france ethiopia second year project cameroon bring advocate international hiv aids alliance colectivo activist public sector ngo medium sol mexico reduce stigma discrimination private sector political academic associate hiv aids thirteen community scientific community organisation help people live hiv aid include gay man sex worker drug gsk frost sullivan global user join project colectivo sol excellence award malaria prevention helping identify impact stigma treatment judge note gsk hiv transmission access service work face challenge malaria key corporate address advocacy medium responsibility issue core business skill local police health service government resource philanthropic community program contribute global effort tackle africa disease commit million million year strengthen integrate hiv personal hygiene sanitation aid treatment general healthcare clinic education phase kenya enable patient avoid stigma year million people die visit dedicated hiv clinic help diarrhoearelate disease child doctor provide ongoing service people develop country death diagnose hiv positive action work easily prevent well hand washing clinic site currently sanitation offer arv treatment kenya identify phase help reduce diarrhoearelate successful approach improve takeup disease encourage school child wash arv treatment hand establish phase global invest million sponsor global village community million programme exhibition workshop area international phase run partnership amref plan aids conference hold toronto canada international save child highlight key issue affect community ministry health education stimulate dialogue networking country global community people attend support project international council aids service organization icaso boost communitybase advocacy gsk corporate responsibility report corporate responsibility report approach donation programme impressive result investment medicine example evaluation datum sample phase gsk follow world health school nicaragua year period local programme organization interagency frequency hand washing guideline drug donation support wide range health education toilet pupil participate school state donation initiative community operate increase fivefold proportion child donation centrally site report diarrhoea week period fall response response local need percent percent express need example send prior consent bangladesh join phase community partnership support major implement school reach label correctly region child far integrate school minimum oneyear health nutrition programme save support health shelf life child phase partner bangladesh europe donate medicine addition longterm support hole disease require phase extend mexico tajikistan wall childrens camp barretstown ireland continuous assure supply operate country lenvol france give total number child reach phase active member programme european partnership quality medical estimate country improve children healthcare donation pqmd alliance future challenge pharmaceutical company major country programme charity encourages plan launch phase kibera kenya africas good practice donation large slum time phase italy read grow read aloud delivery medicine operate informal settlement create programme child neurofunctional model improve children health disability hard urban community romania beacon hope palliative care humanitarian relief programme child multicoloure live russia support multicoloure life gsk donate essential product antibiotic slovakia change advance disease help improve quality help relief effort disaster area support prevention programme child urban life disabled child russia basic healthcare provision impoverished housing estate programme bring community regional charity community spain children shelter provide healthcare foundation government donation request government homeless abandon child moscow gsk russia major charitable organisation thousand child age manufacture specifically partner russia multicoloure life sidebar year old limited health enable charity hold range medicine capability take international stock respond promptly multicoloure life support major public health initiative tackle emergency work partnership communitybase communi hiv aids lymphatic filariasis malaria relief charity include americare direct relief cation tv magazine diarrhoearelate disease develop country workshop school liaison interchurch medical assistance map international exhibition educate project hope addition funding countryspecific gradually change individual programme grant activity perception disable people year donate lifesave medicine gsk russia receive platinum worth million million value wholesale country programme international ounce award leadership price support relief effort community region include multicoloure life russian pharmaceutical industry healthcare country brazil attituda positiva use drama school request medicine educate teenager hiv good help people affect conflict reproductive health controversial require careful management philippine pinoy health pass family health seek ensure equitable treatment approach provide health education direct commitment support health need family low income provision long term support work partner essential drug doctor uk patient clinic hospital gsk support charitable organisation uk include example shipment million support medical research medicine support people displace asthma uk british retinitis pigmentosa conflict lebanon response specific society deafness research uk muscular request humanitarian aid partner dystrophy campaign provide supply augmentin amoxil zinacef zantac lanoxin value product handle partner americare m direct relief gsk corporate responsibility report corporate responsibility report donation support health charity vietnam midwife include princess royal trust carer gsk france foundation support unique training programme base tu du hospital initiative donation support programme country hospital ho chi minh city year develop guideline focus people live hiv aids vietnam project training support gps hospital work develop country aim improve healthcare birth attendant provide carer prevention education training maternal healthcare service new programme implement rural village project aim myasthenia gravis association donation country grant reduce childbirth complication year decrease newborn fatality provide specialist nurse people suffer gsk foundation canada focus hospice unacceptably high level myasthenia gravis chronic auto care help terminally ill patient family percent immune neuromuscular disorder foundation support community support tu du medical programmes africa include aids orphans nursing staff house down syndrome association shift uganda threeyear programme build residential training centre build perspective support gsk trainee spend community support vulnerable child photographic exhibition show people month gain practical luweero district work african medical down syndrome lead rewarding knowledge maternal semiindependent live research foundation amref child healthcare midwife graduate north carolina gsk foundation usa impact award recognise community governmentrecognise endow selffunde organisation support organisation work significantly qualification midwife initiative area mathematics science equip medical improve health year award health education north carolina pack provide range healthcare charity foundation award grant total million motor scooter assist select panel judge hartlepool million access remote area family judge overall winner work bring health service deprive area crisis open christmas hartlepool refit doubledecker bus crisis open christmas offer need support support education homeless people london increase support zone health festive season school obesity programme run north gsk support education uk support crisis carolina prevention partner follow pilot particular emphasis make science follow way programme successfully reach relevant young people support donation food child professional development science teacher clothing gsk employee programme provide elementary middle education programme help increase donation christmas high school north carolina philadelphia pool potential future employee encourage card challenge campaign instead send corporate learning model encourage healthy weight young people pursue science career christmas card nutrition education exercise new component programme include distance science education uk donation learn puppet talk scienceengage scienceis new cover operating cost initiative launch sponsor gsk mobile medical service programme support use puppet increase children visit crisis centre include understand science children health fund referral research nuffield foundation find management initiative rmi help high teacher puppet science lesson risk homeless child receive specialist child treat real character medical care need puppet engage pupil helping solve science problem result child recognise excellence community talk science increase healthcare philadelphia area understand subject particularly glaxosmithkline impact awards year noticeable low achieve child nonprofit organisation receive normally speak lesson typical help continue remark include like talk group work friend teacher understand well foundation puppet gsk operate single charitable foundation invest community investment programme train teacher uk primary school countrybase foundations canada czech use puppet effectively science lesson republic france italy romania spain north school receive book science base carolina local foundation support story animate cd hand hold wide range charity healthcare initiative puppet story puppet face problem science theme ask child help solve gsk corporate responsibility report corporate responsibility report announce funding crest cid employee involvement investigator education project programme run partnership british association encourage employee contribute advancement science provide science local community volunteer benefit activity award school club community employee gain new primary school aim school experience skill child take hundred employee time good support inspire innovative scheme cause day care postdoctoral researcher research support school science education education enable postdoctoral researcher uk science engineering ambassador scheme spend half time specialist science school partnership educational discovery gain postgraduate certificate education uk cash donation pgce charity employee voluntary education work found partner institute gsk investment volunteer excellence competitive workforce business coalition run programme give chamber commerce improve charity employee educational standard partnership partner volunteer hour business education provider make difference programme work national board provide grant professional teaching standard nbpt charity employee provide scholarship endowment volunteer million increase number science teacher national board certify country encourage employee far focusse north carolina donate money charity match money philadelphia expand provide taxefficient way state donation accordance local taxation guideline support range local education initiative help engage young student science gsk match donation example include employee retiree value million million addition gsk give science summer free million match donation gsk programme philadelphia give employee annual gsk united children chance participate way campaign handson experiment science course major sponsor university north carolinas travel science laboratory destiny inception destiny serve approximately underserve secondary school reach student year gsk corporate responsibility report corporate responsibility report datum summary access medicine number country supply preferentially price arvs number preferentially price combivirand epivirtablet ship million number generic arvs supply gsk licencee millions gsk combivirnotforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million research development expenditure rd billion gsk animal research facility accredit association assessment accreditation laboratory animal care number trial publish gsk clinical trial register cumulative total ethical conduct number manager complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity minority ethnic diversity ethnic minority uk lose time injury illness rate case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million value humanitarian product donation include albendazole million number albendazole tablet donate prevention lymphatic filariasis million include arvs sell notforprofit discount price unable collect datum number patient treat include delivery cost mdecin san frontires pricing report list average cost generic equivalent cover animal gsk facility animal research laboratory close laboratory japan aquire laboratory croatia canada establish contract use laboratory singapore make current total gsk laboratory use animal trial complete merger create gsk include contact line manager compliance officer confidential integrity helpline offsite post office box datum include inhaler asia change way calculate datum previous year datum reflect change environmental report detail trademark brand name appear italic publication trademark own andor license gsk associate company gsk corporate responsibility report